

To: Anderson, Van A. (van.anderson@walgreens.com)[van.anderson@walgreens.com]; Bullington, Pamela[pamela.bullington@walgreens.com]
Cc: Palma, Robert[Robert.Palma@pharma.com]; Jeter, Ayisha[Ayisha.Jeter@pharma.com]; Projansky, Steven[Steven.Projansky@pharma.com]; Odell, Morgan[morgan.odell@walgreens.com]; Kadatskaya, Stella[Stella.Kadatskaya@pharma.com]; Devonport, Aimee[Aimee.Devonport@pharma.com]
From: Scifo, Tony
Sent: Fri 6/12/2015 11:12:03 AM
Subject: FW: APPROVED FOR USE: Walgreens email for Pharmacists 2015
[Hysingla MPU 2015- 06.11.15.pdf](#)
[C9901 Hysingla Pharmacist Guide - LOW RESs.pdf](#)
[178121 HYD011 303511-0C Hysingla ER FPI.pdf](#)
[Walgreens Product Update Master Services Agreement Exhibit 1.pdf](#)

Van, Pam:

Attached is the approved email, Pharmacist Guide, FPI and signed SOW for Walgreens MPU. Please let me know when the Pharmacist Guide will be communicated to your stores.
Thank you,
Tony

Tony Scifo
Senior National Account Executive, Purdue
25175 N. Pawnee Rd.
Barrington Illinois 60010
Cell phone 847-224-7143

Please visit: www.purduepharma.com/Products/Prescription/Pages/default.aspx for Full Prescribing Information for all of Purdue's Prescription Products.

From: Devonport, Aimee
Sent: Friday, June 12, 2015 10:47 AM
To: Scifo, Tony
Cc: Palma, Robert; Jeter, Ayisha; Projansky, Steven
Subject: FW: APPROVED FOR USE: Walgreens email for Pharmacists 2015

Hi Tony,

Attached is the approved email, Pharmacist Guide and FPI for Walgreens.

Please let me know if you have any questions.

Thank you,
Aimee

PLAINTIFFS TRIAL
EXHIBIT
P-25990_00001

Manufacturer Product Update – Hysingla® ER (hydrocodone bitartrate) extended-release tablets, CII

Purdue Pharma L.P. introduces Hysingla ER (hydrocodone bitartrate), an extended-release opioid with abuse-deterrent properties. Please read Section 9.2 of the Full Prescribing Information to read about the abuse-deterrent properties of Hysingla ER. It is important to know that abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible.

Please click [here](#) for the Hysingla ER Pharmacist Guide to learn more about Hysingla ER, including Dosing, Pharmacokinetics, Important Safety Information and Important Patient Counseling Information.

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

Addiction, Abuse, and Misuse: HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see *Warnings and Precautions (5.1)*].

Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see *Warnings and Precautions (5.2)*].


Accidental Ingestion: Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see *Warnings and Precautions (5.2)*].

Neonatal Opioid Withdrawal Syndrome: Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see *Warnings and Precautions (5.3)*].

Cytochrome P450 3A4 Interaction: The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see *Warnings and Precautions (5.11), Drug Interactions (7.1), and Clinical Pharmacology (12.3)*].

Please click [here](#) to read the Full Prescribing Information, including Boxed Warning.

Pharmacist's Guide



**A FAMILIAR
MOLECULE,
REENGINEERED**

Please read accompanying Full Prescribing Information, including Boxed Warning on page 2 and back cover.

Indications and Usage

Hysingla[®] ER (hydrocodone bitartrate) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Limitations of Use

- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Hysingla ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain
- Hysingla ER is not indicated as an as-needed analgesic

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

Addiction, Abuse, and Misuse

HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see *Warnings and Precautions (5.1)*].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see *Warnings and Precautions (5.2)*].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can

result in a fatal overdose of hydrocodone [see *Warnings and Precautions (5.2)*].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see *Warnings and Precautions (5.3)*].

Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see *Warnings and Precautions (5.11)*, *Drug Interactions (7.1)*, and *Clinical Pharmacology (12.3)*].

Hysingla ER: The first and only once-daily hydrocodone with abuse-deterrent properties and no acetaminophen

- **One tablet daily provides 24 hours of hydrocodone delivery**
 - Hysingla ER tablets must be taken whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth. Crushing, chewing, or dissolving Hysingla ER will result in uncontrolled delivery of hydrocodone and can lead to overdose or death. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with Hysingla ER
- **The first and only hydrocodone with FDA-approved labeling in section 9.2 that describes abuse-deterrent characteristics**
 - The *in vitro* data demonstrate that Hysingla ER has physical and chemical properties that are expected to deter intranasal and intravenous abuse. The data from the clinical abuse potential studies, along with support from the *in vitro* data, also indicate that Hysingla ER has physicochemical properties that are expected to reduce intranasal abuse and oral abuse when chewed
 - **However, abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible**
 - With parenteral abuse, the inactive ingredients in Hysingla ER can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury
- **Proven effective in a clinical trial**
- **Contains no acetaminophen**
- **Flexibility of 7 dosage strengths – 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg**
 - The starting dose for patients who are not opioid tolerant is Hysingla ER 20 mg orally every 24 hours. Opioid-tolerant patients are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid. Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression

Contraindications


Hysingla ER is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment, known or suspected paralytic ileus and gastrointestinal obstruction, hypersensitivity to any component of Hysingla ER or the active ingredient, hydrocodone bitartrate.

Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets—for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

24-hour hydrocodone delivery with Hysingla ER

ONE HYSINGLA ER TABLET TAKEN AT THE SAME TIME EACH DAY CAN PROVIDE YOUR PATIENTS WITH AROUND-THE-CLOCK HYDROCODONE DELIVERY

- **Steady-state plasma hydrocodone concentrations were confirmed on Day 3 of once-daily dosing of Hysingla ER**
 - During titration, adjust the dose of Hysingla ER in increments of 10 mg to 20 mg every 3 to 5 days as needed to achieve adequate analgesia



- **Median T_{max} values were 14 hours (range: 12 to 24 hours) on both Day 1 and Day 5 following once-daily administration of Hysingla ER for 5 days**

Pharmacokinetic data do not correlate to clinical effects.

WARNINGS AND PRECAUTIONS

Addiction, Abuse, and Misuse

Hysingla ER contains hydrocodone, a Schedule II controlled substance. Hysingla ER exposes users to the risks of opioid addiction, abuse, and misuse. As extended-release products such as Hysingla ER deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of hydrocodone present.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hysingla ER and in those who obtain the drug illicitly. Addiction can occur at recommended doses and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Hysingla ER, and monitor all patients receiving Hysingla ER for the development of these behaviors or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient.

Abuse or misuse of Hysingla ER by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of the hydrocodone and can result in overdose and death.

Opioid agonists such as Hysingla ER are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing Hysingla ER. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug.

Please read accompanying Full Prescribing Information, including Boxed Warning.

4

Additional Important Safety Information for Pharmacists

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression has been reported with the use of modified-release opioids, even when used as recommended, and if not immediately recognized and treated, may lead to respiratory arrest and death.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Hysingla ER, the risk is greatest during the initiation of therapy or following a dose increase. Closely monitor patients for respiratory depression when initiating therapy with Hysingla ER and following dose increases.

To reduce the risk of respiratory depression, proper dosing and titration of Hysingla ER are essential. Overestimating the Hysingla ER dose when converting patients from another opioid product can result in fatal overdose with the first dose.

Accidental ingestion of even one dose of Hysingla ER, especially by children, can result in respiratory depression and death due to an overdose of hydrocodone.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of Hysingla ER during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Use in Elderly, Cachectic, and Debilitated Patients

Closely monitor elderly, cachectic, and debilitated patients, since life-threatening respiratory depression is more likely to occur due to altered pharmacokinetics or clearance, particularly when initiating and titrating Hysingla ER and when given concomitantly with other drugs that depress respiration.

Use in Patients with Chronic Pulmonary Disease

When initiating therapy and titrating with Hysingla ER, monitor patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression. In these patients, even usual therapeutic doses of Hysingla ER may decrease respiratory drive to the point of apnea. Consider the use of alternative non-opioid analgesics in these patients if possible.

Use in Patients with Head Injury and Increased Intracranial Pressure

In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of opioid analgesics and their potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO₂ retention) may be markedly exaggerated. Furthermore, opioid analgesics can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries.

Monitor patients closely who may be susceptible to the intracranial effects of CO₂ retention (e.g., those with evidence of increased intracranial pressure or impaired consciousness). Opioids may obscure the clinical course in a patient with a head injury. Avoid the use of Hysingla ER in patients with impaired consciousness or coma.

Hypotensive Effect

Hysingla ER may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or after concurrent administration with drugs (e.g., phenothiazines or other agents which compromise vasomotor tone). Monitor these patients for signs of hypotension after initiating or titrating the dose of Hysingla ER. In patients with circulatory shock, Hysingla ER may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of Hysingla ER in patients with circulatory shock.

Please see Additional Warnings and Precautions on the preceding and following pages.

5

HYDROCODONE
REENGINEERED

 **Hysingla ER**
(Hydrocodone Bitartrate) 
EXTENDED-RELEASE TABLETS

Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets—for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

FDA labeling for abuse-deterrent opioid formulations

The 4 categories of studies that describe potential abuse-deterrent properties ¹

CATEGORY 1

Laboratory-based *in vitro* manipulation and extraction studies

Evaluate the ease with which the potentially abuse-deterrent properties of a formulation can be defeated or compromised

CATEGORY 2

Pharmacokinetic studies

Evaluate the *in vivo* properties of the formulation by comparing the pharmacokinetic profiles of the manipulated formulation with the intact formulation and with manipulated and intact formulations of the comparator drugs through one or more routes of administration

CATEGORY 3

Clinical abuse potential studies

Assess the impact of potentially abuse-deterrent properties *in vivo*, generally conducted in a drug-experienced, recreational user population

CATEGORY 4

Postmarket studies

Determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting

Additional Important Safety Information for Pharmacists

Gastrointestinal Obstruction, Dysphagia, and Choking

In the clinical studies with specific instructions to take Hysingla ER with water to swallow the tablets, 11 out of 2476 subjects reported difficulty swallowing Hysingla ER. These reports included esophageal obstruction, dysphagia, and choking, one of which had required medical intervention to remove the tablet. Instruct patients not to pre-soak, lick or otherwise wet Hysingla ER tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in the mouth.

Patients with underlying gastrointestinal disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at greater risk of developing these complications. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying gastrointestinal disorders resulting in a small gastrointestinal lumen.

Hysingla ER is the first and only hydrocodone with FDA-approved labeling in section 9.2 that describes abuse-deterrent characteristics

All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

FORMULATED WITH PROPERTIES INTENDED TO MAKE THE TABLET MORE DIFFICULT TO MISUSE AND ABUSE, AND MAINTAINS SOME EXTENDED-RELEASE CHARACTERISTICS IF PHYSICALLY COMPROMISED

- The *in vitro* data demonstrate that Hysingla ER has physical and chemical properties that are expected to deter intranasal and intravenous abuse. The data from the clinical abuse potential studies, along with support from the *in vitro* data, also indicate that Hysingla ER has physicochemical properties that are expected to reduce intranasal abuse and oral abuse when chewed
- **However, abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible**
- With parenteral abuse, the inactive ingredients in Hysingla ER can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury
- Additional data, including epidemiological data, when available, may provide further information on the impact of Hysingla ER on the abuse liability of the drug. Accordingly, section 9.2 (titled *Abuse*) of the Full Prescribing Information may be updated in the future as appropriate

Additional Important Safety Information for Pharmacists

Decreased Bowel Motility

Hysingla ER is contraindicated in patients with gastrointestinal obstruction, including paralytic ileus. Opioids diminish propulsive peristaltic waves in the gastrointestinal tract and decrease bowel motility. Monitor for decreased bowel motility in post-operative patients receiving opioids. The administration of Hysingla ER may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Hydrocodone may cause spasm of the sphincter of Oddi. Monitor patients with biliary tract disease, including acute pancreatitis.

Please read accompanying Full Prescribing Information, including Boxed Warning.

6

Please see Additional Warnings and Precautions on the preceding and following pages.


7

HYDROCODONE
REENGINEERED

 **Hysingla ER**
(Hydrocodone Bitartrate) 
EXTENDED-RELEASE TABLETS

Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets—for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Hysingla ER is the first once-daily hydrocodone, available in 7 dosage strengths



HYSINGLA ER IS TAKEN ONCE EVERY 24 HOURS AND IS AVAILABLE IN 7 DOSAGE STRENGTHS FOR INDIVIDUALIZED TREATMENT

- The starting dose for patients who are not opioid tolerant is Hysingla ER 20 mg orally every 24 hours. Opioid-tolerant patients are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid. Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.

Straightforward conversion for IR hydrocodone patients

- Patients receiving other oral hydrocodone-containing formulations may be converted to Hysingla ER by administering the patient's total daily oral hydrocodone dose as Hysingla ER once daily
- Discontinue all other around-the-clock opioid drugs when Hysingla ER therapy is initiated
- Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy

Total daily dose of IR hydrocodone fixed-combination



Hydrocodone/APAP (7.5 mg/325 mg) 7.5 mg
1 tablet every 6 hours

Starting dose of Hysingla ER



Hysingla ER 30 mg
1 tablet every 24 hours

Not actual tablets. All tablets are in milligrams (mg).
IR=immediate release, ER=extended release, APAP=acetaminophen

Additional Dosing Considerations

- Hysingla ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain
- Hysingla ER tablets must be taken whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth. Crushing, chewing, or dissolving Hysingla ER tablets will result in uncontrolled delivery of hydrocodone and can lead to overdose or death
- Continually re-evaluate patients receiving Hysingla ER to assess the maintenance of pain control and the relative incidence of adverse reactions as well as monitoring for the development of addiction, abuse, or misuse
- Hysingla ER may be administered without regard to meals

Please read accompanying Full Prescribing Information, including Boxed Warning.

8

Titration and maintenance of therapy

- Individually titrate Hysingla ER to a dose that provides adequate analgesia and minimizes adverse reactions
- Continually re-evaluate patients receiving Hysingla ER to assess the maintenance of pain control and the relative incidence of adverse reactions as well as monitoring for the development of addiction, abuse, or misuse
- During chronic therapy, periodically reassess the continued need for the use of opioid analgesics
- Adjust the dose of Hysingla ER in increments of 10 mg to 20 mg every 3 to 5 days as needed to achieve adequate analgesia
- Patients who experience breakthrough pain may require a dose increase of Hysingla ER, or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the Hysingla ER dose
- If unacceptable opioid-related adverse reactions are observed, the next daily dose may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions

DISCONTINUATION OF HYSINGLA ER

- Do not abruptly discontinue Hysingla ER. When the patient no longer requires opioid therapy, use a gradual downward titration of the dose to prevent signs and symptoms of withdrawal in the physically dependent patient. The dose may be reduced every 2 to 4 days. The next dose should be at least 50% of the prior dose. After reaching Hysingla ER 20 mg dose for 2 to 4 days, Hysingla ER can be discontinued

Additional Important Safety Information for Pharmacists

Cytochrome P450 3A4 Inhibitors and Inducers

The clinical results with CYP3A4 inhibitors show an increase in hydrocodone plasma concentrations and possibly increased or prolonged opioid effects, which could be more pronounced with concomitant use of CYP3A4 inhibitors. The expected clinical result with CYP3A4 inducers is a decrease in hydrocodone plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors or inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved.

Interactions with Central Nervous System Depressants

Hypotension, profound sedation, coma, respiratory depression, and death may result if Hysingla ER is used concomitantly with other CNS depressants (e.g., sedatives, anxiolytics, hypnotics, neuroleptics, other opioids). When considering the use of Hysingla ER in a patient taking a CNS depressant, assess the duration of use of the CNS depressant and the patient's response, including the degree of tolerance that has developed to CNS depression. Additionally, evaluate the patient's use of alcohol or illicit drugs that cause CNS depression. If the decision to begin Hysingla ER therapy is made, start with a lower Hysingla ER dose than usual (i.e., 20-30% less), monitor patients for signs of sedation and respiratory depression and consider using a lower dose of the concomitant CNS depressant.

Please see Additional Warnings and Precautions on the preceding and following pages.

9

**HYDROCODONE
REENGINEERED**

Hysingla ER
(Hydrocodone Bitartrate)
EXTENDED-RELEASE TABLETS

Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets—for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Important Patient Counseling Information for Pharmacists About Hysingla ER

Dispense the Medication Guide each time patients pick up their Hysingla ER prescription. It is important to tell patients to read and understand this material before they start taking Hysingla ER and each time they get a refill, as the information may have changed.

Medication Guide

**Hysingla ER (hye-SING-luh)
(hydrocodone bitartrate) Extended-Release Tablets, CII**

Hysingla ER is:

- A strong prescription pain medicine that contains an opioid (narcotic). It is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them
- A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death
- Not for use to treat pain that is not around-the-clock

Important information about Hysingla ER:

- Get emergency help right away if you take too much Hysingla ER (overdose). When you first start taking Hysingla ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur
- Never give anyone else your Hysingla ER. They could die from taking it. Store Hysingla ER away from children and in a safe place to prevent stealing or abuse. Selling or giving away Hysingla ER is against the law

Do not take Hysingla ER if you have:

- severe asthma, trouble breathing, or other lung problems
- a bowel blockage or have narrowing of the stomach or intestines

Before taking Hysingla ER, tell your healthcare provider if you have a history of:

- head injury, seizures
- liver, kidney, thyroid problems
- problems urinating
- pancreas or gallbladder problems

- heart rhythm problems (long QT syndrome)
- abuse of street or prescription drugs, alcohol addiction, or mental health problems

Tell your healthcare provider if you are:

- **pregnant or planning to become pregnant.** Prolonged use of Hysingla ER during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated
- **breastfeeding.** Hysingla ER passes into breast milk and may harm your baby
- taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking Hysingla ER with certain other medicines can cause serious side effects and could lead to death

When taking Hysingla ER:

- Do not change your dose. Take Hysingla ER exactly as prescribed by your healthcare provider
- Take your prescribed dose every 24 hours, at the same time every day. Do not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual time the next day
- Swallow Hysingla ER whole. Do not cut, break, chew, crush, dissolve, snort, or inject Hysingla ER because this may cause you to overdose and die
- Hysingla ER should be taken 1 tablet at a time. Do not pre-soak, lick, or wet the tablet before placing it in your mouth to avoid choking on the tablet

Call your healthcare provider if the dose you are taking does not control your pain.

- **Do not stop taking Hysingla ER without talking to your healthcare provider**
- After you stop taking Hysingla ER, flush any unused tablets down the toilet

While taking Hysingla ER, DO NOT:

- Drive or operate heavy machinery until you know how Hysingla ER affects you. Hysingla ER can make you sleepy, dizzy, or lightheaded
- Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with Hysingla ER may cause you to overdose and die

The possible side effects of Hysingla ER are:

- constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe

Get emergency medical help if you have:

- trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme drowsiness, light-headedness when changing positions, or you are feeling faint

These are not all the possible side effects of Hysingla ER. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.

Please see Additional Warnings and Precautions on the preceding and following pages.

Please read accompanying Full Prescribing Information, including Boxed Warning.

10

11

**HYDROCODONE
REENGINEERED**

 **Hysingla®ER**
(Hydrocodone Bitartrate) 
EXTENDED-RELEASE TABLETS

Hysingla[®] ER (hydrocodone bitartrate) Extended-Release Tablets—for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Addressing addiction, abuse, and misuse

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Hysingla ER, and monitor all patients receiving Hysingla ER for the development of these behaviors or conditions.

Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol addiction or abuse) or mental illness (eg, major depression). The potential for these risks should not, however, prevent the prescribing of Hysingla ER for the proper management of pain in any given patient.

RISKS SPECIFIC TO ABUSE OF HYSINGLA ER

- Hysingla ER contains hydrocodone bitartrate, a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone. Hysingla ER can be abused and is subject to misuse, abuse, addiction and criminal diversion. The high drug content in the extended-release formulation adds to the risk of adverse outcomes from abuse and misuse.
- All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
- Hysingla ER can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by law, is strongly advised.
- Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Additional Important Safety Information for Pharmacists

Driving and Operating Machinery

Hysingla ER may impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Peak blood levels of hydrocodone may occur 14 – 16 hours (range 6 – 30 hours) after initial dosing of Hysingla ER. Blood levels of hydrocodone, in some patients, may be high at the end of 24 hours after repeated-dose administration. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of Hysingla ER and know how they will react to the medication.

Interaction with Mixed Agonist/Antagonist Opioid Analgesics

Avoid the use of mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) in patients who have received, or are receiving, a course of therapy with a full opioid agonist analgesic, including Hysingla ER. In these patients, mixed agonists/antagonists analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.

QTc Interval Prolongation

QTc prolongation has been observed with Hysingla ER following doses of 160 mg. This observation should be considered in making decisions regarding patient monitoring when prescribing Hysingla ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications known to prolong QTc interval.

Hysingla ER should be avoided in patients with congenital long QT syndrome. In patients who develop QTc prolongation, consider reducing the dose by 33 – 50%, or changing to an alternate analgesic.


Please read accompanying Full Prescribing Information, including Boxed Warning.

12

Help Lower Patients' Costs With the Hysingla ER Patient Savings Program*



Hysingla ER TRIAL OFFER
Co-pay as low as \$0
 Receive up to \$125 in co-pay assistance on your first prescription (patient is responsible for any amount that exceeds \$125).
 The Hysingla ER Trial Offer must be used with the first prescription for Hysingla ER. Only new patients are eligible. The Hysingla ER Trial Offer expires 03/31/2016. Cash-paying patients and patients whose prescriptions are covered under Medicare, Medicaid, or other government programs are not eligible.
 Patients with questions, please call 1-855-396-2622 8:00 am - 8:00 pm EST, Monday through Friday.
 Please read accompanying Full Prescribing Information, including Boxed Warning on the cover of brochure, and the Medication Guide.
 ©2014 Purdue Pharma L.P., Stamford, CT 06901-3431 A9907-FTC 11/14



Hysingla ER SAVINGS CARD
 Save up to \$100 on each prescription after paying first \$25. Patient must retain Hysingla ER Savings Card for further savings. Savings Card can only be used when accompanied by a valid prescription for Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets. Offer expires 03/31/2016. Patients whose prescriptions are covered under Medicare, Medicaid, or other government programs are not eligible.
 Patients with questions, please call 1-855-396-2622 8:00 am - 8:00 pm EST, Monday through Friday.
 Please read accompanying Full Prescribing Information, including Boxed Warning on the cover of brochure, and the Medication Guide.
 ©2014 Purdue Pharma L.P., Stamford, CT 06901-3431 A9907-C 11/14

To learn more and download cards visit [Hysingla ER.com](http://HysinglaER.com)

*ELIGIBILITY REQUIREMENTS:

This card cannot be used if prescriptions are covered by: (i) any federal or state healthcare program, including a state medical or pharmaceutical assistance program (Medicare, Medicaid, Medigap, VA, DOD, TRICARE, etc); (ii) Medicare Prescription Drug Program (Part D Program); (iii) insurance in states that have an "all payor" anti-kickback law or insurance that is paying the entire cost of the prescription. Card use must comply with all Terms and Conditions. Patients must meet eligibility requirements. Void where prohibited by law. Patients in VT are not eligible. Patients must meet eligibility requirements. Other restrictions may apply.

TERMS AND CONDITIONS:

Patients must meet eligibility requirements. Patient agrees to report their use of this card to any third party that reimburses them or pays for any part of the prescription price. Patient additionally agrees to not submit any portion of the product dispensed pursuant to this card to a federal or state healthcare program for purposes of counting it toward their out-of-pocket expenses (such as TrOOP under Medicare Part D or Medicaid). This card is not valid with any other program, discount, or incentive involving the covered medication. This offer is not contingent upon any past, present, or future purchases of the covered drug or any other product, and this offer may be rescinded, revoked, or amended without notice. No reproductions. This card is not insurance. This card is void where prohibited or where restricted beyond the terms herein.

RelayHealth eVoucherRx™ Purdue has partnered with RelayHealth to provide automatic savings at the pharmacy on qualified claims with commercial insurance coverage. For convenience, patients who have third-party insurance and visit a participating eVoucher pharmacy will have savings applied automatically for qualified claims—no Savings Card Required. At participating pharmacies, simply submit the patient's prescription and the patient will automatically receive the co-pay savings on qualified claims. For information, please call RelayHealth Customer Support at 1-800-388-2316.

References: 1. *Guidance for Industry: Abuse-Deterrent Opioids — Evaluation and Labeling*. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. April 2015. 2. Data on File. Purdue Pharma L.P.

Additional Important Safety Information for Pharmacists

ADVERSE REACTIONS

Most common treatment-emergent adverse reactions (≥5%) reported by patients treated with Hysingla ER in the clinical trials were constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, and somnolence.

Please see Additional Warnings and Precautions on the preceding and following pages.

HYDROCODONE
REENGINEERED

Hysingla ER
 (Hydrocodone Bitartrate) 
 EXTENDED-RELEASE TABLETS

Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets, CII Available in 7 Dosage Strengths

Hysingla ER Dosage	Dispensing Unit	NDC #
20 mg	Bottle of 60	59011-271-60
30 mg	Bottle of 60	59011-272-60
40 mg	Bottle of 60	59011-273-60
60 mg	Bottle of 60	59011-274-60
80 mg	Bottle of 60	59011-275-60
100 mg	Bottle of 60	59011-276-60
120 mg	Bottle of 60	59011-277-60

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

Addiction, Abuse, and Misuse

HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see *Warnings and Precautions (5.1)*].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see *Warnings and Precautions (5.2)*].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can

result in a fatal overdose of hydrocodone [see *Warnings and Precautions (5.2)*].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see *Warnings and Precautions (5.3)*].

Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see *Warnings and Precautions (5.11)*, *Drug Interactions (7.1)*, and *Clinical Pharmacology (12.3)*].

www.HysinglaER.com

Please read accompanying Full Prescribing Information, including Boxed Warning above.

Purdue is committed to maintaining the highest standards of sales and marketing practices, while continuing to advance the proper treatment of patients. If you have any questions or concerns with Purdue's sales and marketing practices, please contact us at 1-877-787-3831.



©2015 Purdue Pharma L.P., Stamford, CT 06901-3431
C9901 HYD007 4/15



Hysingla™ ER

(hydrocodone bitartrate) extended-release tablets 

20 mg, 30 mg, 40 mg, 60 mg,
80 mg, 100 mg and 120 mg

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HYSINGLA™ ER safely and effectively. See full prescribing information for HYSINGLA ER.

HYSINGLA™ ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII Initial U.S. Approval: 1943

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

See full prescribing information for complete boxed warning.

- HYSINGLA™ ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing, and monitor regularly for development of these behaviors or conditions. (5.1)
- Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Instruct patients to swallow HYSINGLA ER whole to avoid exposure to a potentially fatal dose of hydrocodone. (5.2)
- Accidental ingestion of HYSINGLA ER, especially by children, can result in fatal overdose of hydrocodone. (5.2)
- Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (5.3)
- Initiation of CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone from HYSINGLA ER. (5.11, 7.1, 12.3)

-----INDICATIONS AND USAGE-----

HYSINGLA ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (1)

Limitations of Use

- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended

doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve HYSINGLA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. (1)

- HYSINGLA ER is not indicated as an as-needed (prn) analgesic. (1)

---DOSAGE AND ADMINISTRATION---

- For opioid-naïve patients, initiate with 20 mg tablets orally every 24 hours. (2.1)
- To convert to HYSINGLA ER from another opioid, follow the conversion instructions to obtain an estimated dose. (2.1)
- Dose titration of HYSINGLA ER may occur every 3 to 5 days (2.2)
- Tablets must be swallowed intact and are not to be crushed, dissolved, or chewed, due to the risk of overdose or death. (2.3, 5.1)
- Do not abruptly discontinue HYSINGLA ER in a physically dependent patient. (2.6)
- HYSINGLA ER tablets should be taken one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth (2.1, 5.9)

-DOSAGE FORMS AND STRENGTHS--

Extended-release Tablets: 20, 30, 40, 60, 80, 100, and 120 mg (3)

-----CONTRAINDICATIONS-----

- Significant respiratory depression (4)
- Acute or severe bronchial asthma (4)
- Known or suspected paralytic ileus and GI obstruction (4)
- Hypersensitivity to any components of HYSINGLA ER or the active ingredient, hydrocodone bitartrate (4)

---WARNINGS AND PRECAUTIONS---

- Misuse, abuse, and diversion: HYSINGLA ER is an opioid agonist and a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone. (5.1)
- Interactions with CNS depressants: Concomitant use may cause profound sedation, respiratory depression, and death. If co-administration is required, consider dose reduction of one or both drugs. (5.4)
- Elderly, cachectic, debilitated patients, and those with chronic pulmonary disease: Monitor closely because of increased risk for life-threatening respiratory depression. (5.5, 5.6)
- Patients with head injury or increased intracranial pressure: Monitor for sedation and respiratory depression. Avoid use of HYSINGLA ER in patients with impaired consciousness or coma susceptible to intracranial effects of CO₂ retention. (5.7)
- Risk of Choking/GI Obstruction: Use with caution in patients who have difficulty swallowing or have underlying GI disorders that may predispose them to obstruction. (5.9, 5.10)

- Concomitant use of CYP3A4 inhibitors may increase opioid effects. (5.11)
- Impaired mental/physical abilities: Caution must be used with potentially hazardous activities. (5.12)
- QTc prolongation has been observed with HYSINGLA ER following daily doses of 160 mg. Avoid use in patients with congenital long QTc syndrome. This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. In patients who develop QTc prolongation, consider reducing the dose. (5.14, 12.2)

-----ADVERSE REACTIONS-----

Most common treatment-emergent adverse events (≥5%) are constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, and somnolence. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----DRUG INTERACTIONS-----

- The CYP3A4 isoenzyme plays a major role in the metabolism of HYSINGLA ER. Drugs that inhibit CYP3A4 activity may cause decreased clearance of hydrocodone which could lead to an increase in hydrocodone plasma concentrations. (7.1)
- CNS depressants: Increased risk of respiratory depression, hypotension, profound sedation, coma or death. When combined therapy with CNS depressant is contemplated, the dose of one or both agents should be reduced. (7.2)
- Mixed Agonists/Antagonists: May precipitate withdrawal or decrease analgesic effect if given concurrently with HYSINGLA ER. (7.3)
- The use of MAO inhibitors or tricyclic antidepressants with HYSINGLA ER may increase the effect of either the antidepressant or HYSINGLA ER. (7.4)

---USE IN SPECIFIC POPULATIONS---

- Pregnancy: Based on animal data, may cause fetal harm. (8.1)
- Nursing Mothers: Discontinue nursing or discontinue drug. (8.3)
- Hepatic impairment: Use half the initial dose of HYSINGLA ER in patients with severe hepatic impairment and monitor closely for adverse events such as respiratory depression. (8.6)
- Renal impairment: Use half the initial dose of HYSINGLA ER in patients with moderate and severe renal impairment and end-stage renal disease and monitor closely for adverse events such as respiratory depression. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 02/2015

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Initial Dosing
- 2.2 Titration and Maintenance of Therapy
- 2.3 Administration of HYSINGLA ER
- 2.4 Patients with Hepatic Impairment
- 2.5 Patients with Renal Impairment
- 2.6 Discontinuation of HYSINGLA ER

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Addiction, Abuse, and Misuse
- 5.2 Life-Threatening Respiratory Depression
- 5.3 Neonatal Opioid Withdrawal Syndrome
- 5.4 Interactions with Central Nervous System Depressants
- 5.5 Use in Elderly, Cachectic, and Debilitated Patients

- 5.6 Use in Patients with Chronic Pulmonary Disease
- 5.7 Use in Patients with Head Injury and Increased Intracranial Pressure
- 5.8 Hypotensive Effect
- 5.9 Gastrointestinal Obstruction, Dysphagia, and Choking
- 5.10 Decreased Bowel Motility
- 5.11 Cytochrome P450 3A4 Inhibitors and Inducers
- 5.12 Driving and Operating Machinery
- 5.13 Interaction with Mixed Agonist/Antagonist Opioid Analgesics
- 5.14 QT Interval Prolongation

6 ADVERSE REACTIONS

- 6.1 Clinical Trial Experience

7 DRUG INTERACTIONS

- 7.1 Drugs Affecting Cytochrome P450 Isoenzymes
- 7.2 Central Nervous System Depressants
- 7.3 Interactions with Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics
- 7.4 MAO Inhibitors
- 7.5 Anticholinergics
- 7.6 Strong Laxatives

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery

- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

10 OVERDOSAGE

- 10.1 Symptoms
- 10.2 Treatment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Moderate to Severe Chronic Lower Back Pain Study

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the Full Prescribing Information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

Addiction, Abuse, and Misuse

HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see *Warnings and Precautions* (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see *Warnings and Precautions* (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see *Warnings and Precautions* (5.2)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal

syndrome and ensure that appropriate treatment will be available [see *Warnings and Precautions* (5.3)].

Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see *Warnings and Precautions* (5.11), *Drug Interactions* (7.1), and *Clinical Pharmacology* (12.3)].

1 INDICATIONS AND USAGE

HYSINGLA ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Limitations of Use

- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve HYSINGLA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- HYSINGLA ER is not indicated as an as-needed analgesic.

2 DOSAGE AND ADMINISTRATION

2.1 Initial Dosing

HYSINGLA ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience and risk factors for addiction, abuse, and misuse [see *Warnings and Precautions (5.1)*]. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with HYSINGLA ER [see *Warnings and Precautions (5.2)*].

HYSINGLA ER is administered orally once daily (every 24 hours). HYSINGLA ER tablets must be taken whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth [see *Patient Counseling Information (17)*]. Crushing, chewing, or dissolving HYSINGLA ER tablets will result in uncontrolled delivery of hydrocodone and can lead to overdose or death [see *Warnings and Precautions (5.1)*].

Use of HYSINGLA ER as the First Opioid Analgesic

Initiate therapy with HYSINGLA ER 20 mg orally every 24 hours.

Use of HYSINGLA ER in Patients who are not Opioid Tolerant

The starting dose for patients who are not opioid tolerant is HYSINGLA ER 20 mg orally every 24 hours. Opioid tolerant patients are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid.

Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression [see *Warnings and Precautions (5.2)*]. Daily doses of HYSINGLA ER greater than or equal to 80 mg are only for use in opioid tolerant patients.

Conversion from Oral Hydrocodone Formulations to HYSINGLA ER

Patients receiving other oral hydrocodone-containing formulations may be converted to HYSINGLA ER by administering the patient's total daily oral hydrocodone dose as HYSINGLA ER once daily.

Conversion from Other Oral Opioids to HYSINGLA ER

Discontinue all other around-the-clock opioid drugs when HYSINGLA ER therapy is initiated.

Although tables of oral and parenteral equivalents are readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and formulations. As such, it is preferable to underestimate a patient's 24-hour oral hydrocodone requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour oral hydrocodone requirements and manage an adverse reaction.

To obtain the initial HYSINGLA ER dose, first use Table 1 to convert the prior oral opioids to a total hydrocodone daily dose and then reduce the calculated daily hydrocodone dose by 25% to account for interpatient variability in relative potency of different opioids.

Consider the following when using the information found in Table 1.

- This is **not** a table of equianalgesic doses.
- The conversion factors in this table are only for the conversion **from** one of the listed oral opioid analgesics to HYSINGLA ER.
- The table **cannot** be used to convert **from** HYSINGLA ER to another opioid. Doing so will result in an over-estimation of the dose of the new opioid and may result in fatal overdose

Table 1. Conversion factors to HYSINGLA ER (Not Equianalgesic Doses)

Opioid	Oral dose (mg)	Approximate oral conversion factor
Codeine	133	0.15
Hydromorphone	5	4
Methadone	13.3	1.5
Morphine	40	0.5
Oxycodone	20	1
Oxymorphone	10	2
Tramadol	200	0.1

To calculate the estimated total hydrocodone daily dose using Table 1:

- For patients on a single opioid, sum the current total daily dose of the opioid and then multiply the total daily dose by the approximate oral conversion factor to calculate the approximate oral hydrocodone daily dose.

- For patients on a regimen of more than one opioid, calculate the approximate oral hydrocodone dose for each opioid and sum the totals to obtain the approximate oral hydrocodone daily dose.
- For patients on a regimen of fixed-ratio opioid/non-opioid analgesic products, use only the opioid component of these products in the conversion.

- Reduce the calculated daily oral hydrocodone dose by 25%

Always round the dose down, if necessary, to the nearest HYSINGLA ER tablet strength available and initiate therapy with that dose. If the converted HYSINGLA ER dose using Table 1 is less than 20 mg, initiate therapy with HYSINGLA ER 20 mg.

Example conversion from a single opioid to HYSINGLA ER:

For example, a total daily dose of oxycodone 50 mg would be converted to hydrocodone 50 mg based on the table above, and then multiplied by 0.75 (ie, take a 25 % reduction) resulting in a dose of 37.5 mg hydrocodone. Round this down to the nearest dose strength available, HYSINGLA ER 30 mg, to initiate therapy.

Close observation and frequent titration are warranted until pain management is stable on the new opioid. Monitor patients for signs and symptoms of opioid withdrawal or for signs of over-sedation/toxicity after converting patients to HYSINGLA ER.

The dose of HYSINGLA ER can be gradually adjusted every three to five days, using increments of 10 to 20 mg, until adequate pain relief and acceptable tolerability have been achieved.

Conversion from Methadone to HYSINGLA ER

Close monitoring is of particular importance when converting from methadone to other opioid agonists. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.

Conversion from Transdermal Fentanyl to HYSINGLA ER

Eighteen hours following the removal of the transdermal fentanyl patch, HYSINGLA ER treatment can be initiated. For each 25 mcg/hr fentanyl transdermal patch, a dose of HYSINGLA ER 20 mg every 24 hours represents a conservative initial dose. Follow the patient closely during conversion from transdermal fentanyl to HYSINGLA ER, as there is limited experience with this conversion.

Conversion from Transdermal Buprenorphine to HYSINGLA ER

All patients receiving transdermal buprenorphine (≤ 20 mcg/hr) should initiate therapy with HYSINGLA ER 20 mg every 24 hours. Follow the patient closely during conversion from transdermal buprenorphine to HYSINGLA ER, as there is limited experience with this conversion.

2.2 Titration and Maintenance of Therapy

Individually titrate HYSINGLA ER to a dose that provides adequate analgesia and minimizes adverse reactions. Continually re-evaluate patients receiving HYSINGLA ER to assess the maintenance of pain control and the relative incidence of adverse reactions as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for the use of opioid analgesics.

Adjust the dose of HYSINGLA ER in increments of 10 mg to 20 mg every 3 to 5 days as needed to achieve adequate analgesia.

Patients who experience breakthrough pain may require a dose increase of HYSINGLA ER, or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the HYSINGLA ER dose.

If unacceptable opioid-related adverse reactions are observed, the next daily dose may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

2.3 Administration of HYSINGLA ER

HYSINGLA ER is administered once daily (every 24 hours).

HYSINGLA ER must be taken whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth [see *Patient Counseling Information (17)*].

Crushing, chewing, or dissolving HYSINGLA ER tablets will result in

uncontrolled delivery of hydrocodone and can lead to overdose or death [see *Warnings and Precautions* (5.1)].

Multiple tablets of lower dose strengths that provide the desired total daily dose can be taken as a once daily dose.

2.4 Patients with Hepatic Impairment

Patients with severe hepatic impairment may have higher plasma concentrations than those with normal function. Initiate therapy with ½ the initial dose of HYSINGLA ER in these patients and monitor closely for respiratory depression and sedation [see *Clinical Pharmacology* (12.3)].

2.5 Patients with Renal Impairment

Patients with moderate to severe renal impairment, and end-stage renal disease may have higher plasma concentrations than those with normal function. Initiate therapy with ½ the initial dose of HYSINGLA ER in these patients and monitor closely for respiratory depression and sedation [see *Clinical Pharmacology* (12.3)].

2.6 Discontinuation of HYSINGLA ER

Do not abruptly discontinue HYSINGLA ER. When the patient no longer requires opioid therapy, use a gradual downward titration of the dose to prevent signs and symptoms of withdrawal in the physically dependent patient. The dose may be reduced every 2-4 days. The next dose should be at least 50% of the prior dose. After reaching HYSINGLA ER 20 mg dose for 2-4 days, HYSINGLA ER can be discontinued.

3 DOSAGE FORMS AND STRENGTHS

- 20 mg film-coated extended-release tablets (round, green-colored, bi-convex tablets printed with “HYD 20”)
- 30 mg film-coated extended-release tablets (round, yellow-colored, bi-convex tablets printed with “HYD 30”)
- 40 mg film-coated extended-release tablets (round, grey-colored, bi-convex tablets printed with “HYD 40”)
- 60 mg film-coated extended-release tablets (round, beige-colored, bi-convex tablets printed with “HYD 60”)
- 80 mg film-coated extended-release tablets (round, pink-colored, bi-convex tablets printed with “HYD 80”)
- 100 mg film-coated extended-release tablets (round, blue-colored, bi-convex tablets printed with “HYD 100”)
- 120 mg film-coated extended-release tablets (round, white-colored, bi-convex tablets printed with “HYD 120”)

4 CONTRAINDICATIONS

HYSINGLA ER is contraindicated in patients with:

- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected paralytic ileus and gastrointestinal obstruction
- Hypersensitivity to any component of HYSINGLA ER or the active ingredient, hydrocodone bitartrate

5 WARNINGS AND PRECAUTIONS

5.1 Addiction, Abuse, and Misuse

HYSINGLA ER contains hydrocodone, a Schedule II controlled substance. As an opioid, HYSINGLA ER exposes users to the risks of addiction, abuse, and misuse [see *Drug Abuse and Dependence* (9.1)]. As extended-release products such as HYSINGLA ER deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of hydrocodone present.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed HYSINGLA ER and in those who obtain the drug illicitly. Addiction can occur at recommended doses and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing HYSINGLA ER, and monitor all patients receiving HYSINGLA ER for the development of these behaviors or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol addiction or abuse) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the prescribing of HYSINGLA ER for the proper management of pain in any given patient.

Abuse or misuse of HYSINGLA ER by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of the hydrocodone and can result in overdose and death [see *Drug Abuse and Dependence* (9.1), and *Overdosage* (10)].

Opioid agonists are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing HYSINGLA ER. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see *Patient Counseling Information* (17)]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

5.2 Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression has been reported with the use of modified-release opioids, even when used as recommended. Respiratory depression from opioid use, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see *Overdosage* (10.2)]. Carbon dioxide (CO₂) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of HYSINGLA ER, the risk is greatest during the initiation of therapy or following a dose increase. Closely monitor patients for respiratory depression when initiating therapy with HYSINGLA ER and following dose increases.

To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential [see *Dosage and Administration* (2.1, 2.2)]. Overestimating the HYSINGLA ER dose when converting patients from another opioid product can result in fatal overdose with the first dose.

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in respiratory depression and death due to an overdose of hydrocodone.

5.3 Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn.

5.4 Interactions with Central Nervous System Depressants

Hypotension, profound sedation, coma, respiratory depression, and death may result if HYSINGLA ER is used concomitantly with alcohol or other central nervous system (CNS) depressants (e.g., sedatives, anxiolytics, hypnotics, neuroleptics, other opioids).

When considering the use of HYSINGLA ER in a patient taking a CNS depressant, assess the duration of use of the CNS depressant and the patient's response, including the degree of tolerance that has developed to CNS depression. Additionally, evaluate the patient's use of alcohol or illicit drugs that cause CNS depression. If the decision to begin HYSINGLA ER is made, start with a lower HYSINGLA ER dose than usual (i.e., 20-30% less), monitor patients for signs of sedation and respiratory depression, and consider using a lower dose of the concomitant CNS depressant [see *Drug Interactions* (7.2)].

5.5 Use in Elderly, Cachectic, and Debilitated Patients

Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Monitor such patients closely, particularly when initiating and titrating HYSINGLA ER and when HYSINGLA ER is given concomitantly with other

drugs that depress respiration [see *Warnings and Precautions (5.2)*].

5.6 Use in Patients with Chronic Pulmonary Disease

Monitor patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression for respiratory depression, particularly when initiating therapy and titrating with HYSINGLA ER, as in these patients, even usual therapeutic doses of HYSINGLA ER may decrease respiratory drive to the point of apnea [see *Warnings and Precautions (5.2)*]. Consider the use of alternative non-opioid analgesics in these patients if possible.

5.7 Use in Patients with Head Injury and Increased Intracranial Pressure

In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of opioid analgesics and their potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO₂ retention) may be markedly exaggerated. Furthermore, opioid analgesics can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries.

Monitor patients closely who may be susceptible to the intracranial effects of CO₂ retention, such as those with evidence of increased intracranial pressure or impaired consciousness. Opioids may obscure the clinical course of a patient with a head injury.

Avoid the use of HYSINGLA ER in patients with impaired consciousness or coma.

5.8 Hypotensive Effect

HYSINGLA ER may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an added risk to individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. Monitor these patients for signs of hypotension after initiating or titrating the dose of HYSINGLA ER. In patients with circulatory shock, HYSINGLA ER may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of HYSINGLA ER in patients with circulatory shock.

5.9 Gastrointestinal Obstruction, Dysphagia, and Choking

In the clinical studies with specific instructions to take HYSINGLA ER with adequate water to swallow the tablet, 11 out of 2476 subjects reported difficulty swallowing HYSINGLA ER. These reports included esophageal obstruction, dysphagia, and choking, one of which had required medical intervention to remove the tablet [see *Adverse Reactions (6)*].

Instruct patients not to pre-soak, lick, or otherwise wet HYSINGLA ER tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in the mouth [see *Patient Counseling Information (17)*].

Patients with underlying gastrointestinal disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at greater risk of developing these complications. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying gastrointestinal disorders resulting in a small gastrointestinal lumen.

5.10 Decreased Bowel Motility

HYSINGLA ER is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus. Opioids diminish propulsive peristaltic waves in the gastrointestinal tract and decrease bowel motility. Monitor for decreased bowel motility in post-operative patients receiving opioids. The administration of HYSINGLA ER may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Hydrocodone may cause spasm of the sphincter of Oddi. Monitor patients with biliary tract disease, including acute pancreatitis.

5.11 Cytochrome P450 3A4 Inhibitors and Inducers

Since the CYP3A4 isoenzyme plays a major role in the metabolism of HYSINGLA ER, drugs that alter CYP3A4 activity may cause changes in clearance of hydrocodone which could lead to changes in hydrocodone plasma concentrations.

The clinical results with CYP3A4 inhibitors show an increase in hydrocodone plasma concentrations and possibly increased or prolonged opioid effects, which could be more pronounced with concomitant use of CYP3A4 inhibitors. The expected clinical result with CYP3A4 inducers is a decrease in hydrocodone plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

If co-administration is necessary, caution is advised when initiating HYSINGLA ER treatment in patients currently taking, or discontinuing, CYP3A4 inhibitors or inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved [see *Drug Interactions (7.1)*].

5.12 Driving and Operating Machinery

HYSINGLA ER may impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Peak blood levels of hydrocodone may occur 14 – 16 hours (range 6 – 30 hours) after initial dosing of HYSINGLA ER tablet administration. Blood levels of hydrocodone, in some patients, may be high at the end of 24 hours after repeated-dose administration. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of HYSINGLA ER and know how they will react to the medication [see *Clinical Pharmacology (12.3)*].

5.13 Interaction with Mixed Agonist/Antagonist Opioid Analgesics

Avoid the use of mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) in patients who have received, or are receiving, a course of therapy with a full opioid agonist analgesic, including HYSINGLA ER. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.

5.14 QTc Interval Prolongation

QTc prolongation has been observed with HYSINGLA ER following daily doses of 160 mg [see *Clinical Pharmacology (12.2)*]. This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. HYSINGLA ER should be avoided in patients with congenital long QT syndrome. In patients who develop QTc prolongation, consider reducing the dose by 33 – 50%, or changing to an alternate analgesic.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Addiction, Abuse, and Misuse [see *Warnings and Precautions (5.1)*]
- Life-Threatening Respiratory Depression [see *Warnings and Precautions (5.2)*]
- Neonatal Opioid Withdrawal Syndrome [see *Warnings and Precautions (5.3)*]
- Interactions with Other CNS Depressants [see *Warnings and Precautions (5.4)*]
- Hypotensive Effects [see *Warnings and Precautions (5.8)*]
- Gastrointestinal Effects [see *Warnings and Precautions (5.9, 5.10)*]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 1,827 patients were treated with HYSINGLA ER in controlled and open-label chronic pain clinical trials. Five hundred patients were treated for 6 months and 364 patients were treated for 12 months. The clinical trial population consisted of opioid-naïve and opioid-experienced patients with persistent moderate to severe chronic pain.

The common adverse reactions (≥2%) reported by patients in clinical trials comparing HYSINGLA ER (20-120 mg/day) with placebo are shown in Table 2 below:

Table 2: Adverse Reactions Reported in $\geq 2\%$ of Patients during the Open-Label Titration Period and Double-Blind Treatment Period: Opioid-Naïve and Opioid-Experienced Patients

MedDRA Preferred Term	Open-Label Titration Period	Double-Blind Treatment Period	
	(N=905) (%)	Placebo (N=292) (%)	HYSINGLA ER (N=296) (%)
Nausea	16	5	8
Constipation	9	2	3
Vomiting	7	3	6
Dizziness	7	2	3
Headache	7	2	2
Somnolence	5	1	1
Fatigue	4	1	1
Pruritus	3	<1	0
Tinnitus	2	1	2
Insomnia	2	2	3
Decreased appetite	1	1	2
Influenza	1	1	3

The adverse reactions seen in controlled and open-label chronic pain studies are presented below in the following manner: most common ($\geq 5\%$), common ($\geq 1\%$ to $<5\%$), and less common ($<1\%$).

The most common adverse reactions ($\geq 5\%$) reported by patients treated with HYSINGLA ER in the chronic pain clinical trials were constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, somnolence.

The common ($\geq 1\%$ to $<5\%$) adverse events reported by patients treated with HYSINGLA ER in the chronic pain clinical trials organized by MedDRA (Medical Dictionary for Regulatory Activities) System Organ Class were:

<i>Ear and labyrinth disorders</i>	tinnitus
<i>Gastrointestinal disorders</i>	abdominal pain, abdominal pain upper, diarrhea, dry mouth, dyspepsia, gastroesophageal reflux disease
<i>General disorders and administration site conditions</i>	chest pain, chills, edema peripheral, pain, pyrexia
<i>Infections and infestations</i>	bronchitis, gastroenteritis, gastroenteritis viral, influenza, nasopharyngitis, sinusitis, urinary tract infection
<i>Injury, poisoning and procedural complications</i>	fall, muscle strain
<i>Metabolism and nutrition disorders</i>	decreased appetite
<i>Musculoskeletal and connective tissue disorders</i>	arthralgia, back pain, muscle spasms, musculoskeletal pain, myalgia, pain in extremity
<i>Nervous system disorders</i>	lethargy, migraine, sedation
<i>Psychiatric disorders</i>	anxiety, depression, insomnia
<i>Respiratory, thoracic and mediastinal disorders</i>	cough, nasal congestion, oropharyngeal pain
<i>Skin and subcutaneous tissue disorders</i>	hyperhidrosis, pruritus, rash
<i>Vascular disorders</i>	hot flush, hypertension

Other less common adverse reactions that were seen in $<1\%$ of the patients in the HYSINGLA ER chronic pain clinical trials include the following in alphabetical order: abdominal discomfort, abdominal distention, agitation, asthenia, choking, confusional state, depressed mood, drug hypersensitivity, drug withdrawal syndrome, dysphagia, dyspnea,

esophageal obstruction, flushing, hypogonadism, hypotension, hypoxia, irritability, libido decreased, malaise, mental impairment, mood altered, muscle twitching, edema, orthostatic hypotension, palpitations, presyncope, retching, syncope, thinking abnormal, thirst, tremor, and urinary retention.

7 DRUG INTERACTIONS

7.1 Drugs Affecting Cytochrome P450 Isoenzymes

Inhibitors of CYP3A4

Co-administration of HYSINGLA ER with ketoconazole, a strong CYP3A4 inhibitor, significantly increased the plasma concentrations of hydrocodone. Inhibition of CYP3A4 activity by inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. Caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved [see *Clinical Pharmacology* (12.3)].

Inducers of CYP3A4

CYP3A4 inducers may induce the metabolism of hydrocodone and, therefore, may cause increased clearance of the drug which could lead to a decrease in hydrocodone plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who had developed physical dependence to hydrocodone. If co-administration with HYSINGLA ER is necessary, monitor for signs of opioid withdrawal and consider dose adjustments until stable drug effects are achieved [see *Clinical Pharmacology* (12.3)].

7.2 Central Nervous System Depressants

The concomitant use of HYSINGLA ER with other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and alcohol can increase the risk of respiratory depression, profound sedation, coma and death. Monitor patients receiving CNS depressants and HYSINGLA ER for signs of respiratory depression, sedation and hypotension.

When combined therapy with any of the above medications is considered, the dose of one or both agents should be reduced [see *Warnings and Precautions* (5.4)].

7.3 Interactions with Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics

Mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) and partial agonist analgesics (buprenorphine) may reduce the analgesic effect of HYSINGLA ER or precipitate withdrawal symptoms in these patients. Avoid the use of mixed agonist/antagonist and partial agonist analgesics in patients receiving HYSINGLA ER.

7.4 MAO Inhibitors

HYSINGLA ER is not recommended for use in patients who have received MAO inhibitors within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics. No specific interaction between hydrocodone and MAO inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.

7.5 Anticholinergics

Anticholinergics or other drugs with anticholinergic activity when used concurrently with opioid analgesics may increase the risk of urinary retention or severe constipation, which may lead to paralytic ileus. Monitor patients for signs of urinary retention and constipation in addition to respiratory and central nervous system depression when HYSINGLA ER is used concurrently with anticholinergic drugs.

7.6 Strong Laxatives

Concomitant use of HYSINGLA ER with strong laxatives (e.g., lactulose), that rapidly increase gastrointestinal motility, may decrease hydrocodone absorption and result in decreased hydrocodone plasma levels. If HYSINGLA ER is used in these patients, closely monitor for the development of adverse events as well as changing analgesic requirements.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

Risk Summary

There are no adequate and well-controlled studies of HYSINGLA ER use during pregnancy. Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. In animal reproduction studies with hydrocodone in rats and rabbits no embryotoxicity or teratogenicity was observed. However, reduced pup survival rates, reduced fetal/pup body weights, and delayed ossification were observed at doses causing maternal toxicity. In all of the studies conducted, the exposures in animals were less than the human exposure (see Animal Data). HYSINGLA ER should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Clinical Considerations

Fetal/neonatal adverse reactions

Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see *Warnings and Precautions* (5.3)].

Data

Animal Data

No evidence of embryotoxicity or teratogenicity was observed after oral administration of hydrocodone throughout the period of organogenesis in rats and rabbits at doses up to 30 mg/kg/day (approximately 0.1 and 0.3-fold, respectively, the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons). However, in these studies, reduced fetal body weights and delayed ossification were observed in rat at 30 mg/kg/day and reduced fetal body weights were observed in rabbit at 30 mg/kg/day (approximately 0.1 and 0.3-fold, respectively, the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons). In a pre- and post-natal development study pregnant rats were administered oral hydrocodone throughout the period of gestation and lactation. At a dose of 30 mg/kg/day decreased pup viability, pup survival indices, litter size and pup body weight were observed. This dose is approximately 0.1-fold the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons.

8.2 Labor and Delivery

Opioids cross the placenta and may produce respiratory depression in neonates. HYSINGLA ER is not recommended for use in women immediately prior to and during labor, when use of shorter acting analgesics or other analgesic techniques are more appropriate. HYSINGLA ER may prolong labor through actions which temporarily reduce the strength, duration and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor.

8.3 Nursing Mothers

Hydrocodone is present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue HYSINGLA ER, taking into account the importance of the drug to the mother. Infants exposed to HYSINGLA ER through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breast-fed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.

8.4 Pediatric Use

The safety and effectiveness of HYSINGLA ER in pediatric patients have not been established.

Accidental ingestion of a single dose of HYSINGLA ER in children can result in a fatal overdose of hydrocodone [see *Warnings and Precautions* (5.2)].

HYSINGLA ER gradually forms a viscous hydrogel (i.e., a gelatinous mass) when exposed to water or other fluids. Pediatric patients may be at increased risk of esophageal obstruction, dysphagia, and choking because of a smaller gastrointestinal lumen if they ingest HYSINGLA ER [see *Warnings and Precautions* (5.9)].

8.5 Geriatric Use

In a controlled pharmacokinetic study, elderly subjects (greater than 65 years) compared to young adults had similar plasma concentrations of hydrocodone [see *Clinical Pharmacology* (12.3)]. Of the 1827 subjects exposed to HYSINGLA ER in the pooled chronic pain studies, 241 (13%) were age 65 and older (including those age 75 and older), while 42 (2%) were age 75 and older. In clinical trials with appropriate initiation of therapy and dose titration, no untoward or unexpected adverse reactions were seen in the elderly patients who received HYSINGLA ER.

Hydrocodone may cause confusion and over-sedation in the elderly. In addition, because of the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease and concomitant use of CNS active medications, start elderly patients on low doses of HYSINGLA ER and monitor closely for adverse events such as respiratory depression, sedation, and confusion.

8.6 Hepatic Impairment

No adjustment in starting dose with HYSINGLA ER is required in patients with mild or moderate hepatic impairment. Patients with severe hepatic impairment may have higher plasma concentrations than those with normal hepatic function. Initiate therapy with 1/2 the initial dose of HYSINGLA ER in patients with severe hepatic impairment and monitor closely for adverse events such as respiratory depression [see *Clinical Pharmacology* (12.3)].

8.7 Renal Impairment

No dose adjustment is needed in patients with mild renal impairment. Patients with moderate or severe renal impairment or end stage renal disease have higher plasma concentrations than those with normal renal function. Initiate therapy with 1/2 the initial dose of HYSINGLA ER in these patients and monitor closely for adverse events such as respiratory depression [see *Clinical Pharmacology* (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

HYSINGLA ER contains hydrocodone bitartrate, a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone. HYSINGLA ER can be abused and is subject to misuse, abuse, addiction and criminal diversion. The high drug content in the extended-release formulation adds to the risk of adverse outcomes from abuse and misuse.

9.2 Abuse

All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Drug abuse is the intentional non-therapeutic use of an over-the-counter or prescription drug, even once, for its rewarding psychological or physiological effects. Drug abuse includes, but is not limited to the following examples: the use of a prescription or over-the-counter drug to get "high," or the use of steroids for performance enhancement and muscle build up.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and include: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

"Drug-seeking" behavior is very common to addicts and drug abusers. Drug seeking tactics include, but are not limited to, emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers, people with untreated addiction, and criminals seeking drugs to sell. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical

dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

HYSINGLA ER can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Abuse may occur by taking intact tablets in quantities greater than prescribed or without legitimate purpose, by crushing and chewing or snorting the crushed formulation, or by injecting a solution made from the crushed formulation. The risk is increased with concurrent use of HYSINGLA ER with alcohol or other central nervous system depressants.

Risks Specific to Abuse of HYSINGLA ER

HYSINGLA ER is for oral use only. Abuse of HYSINGLA ER poses a risk of overdose and death. Taking cut, broken, chewed, crushed, or dissolved HYSINGLA ER increases the risk of overdose and death.

With parenteral abuse, the inactive ingredients in HYSINGLA ER can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases, such as hepatitis and HIV.

Abuse Deterrence Studies

HYSINGLA ER is formulated with physicochemical properties intended to make the tablet more difficult to manipulate for misuse and abuse, and maintains some extended release characteristics even if the tablet is physically compromised. To evaluate the ability of these physicochemical properties to reduce the potential for abuse of HYSINGLA ER, a series of *in vitro* laboratory studies, pharmacokinetic studies and clinical abuse potential studies were conducted. A summary is provided at the end of this section.

In Vitro Testing

In vitro physical and chemical tablet manipulation studies were performed to evaluate the success of different extraction methods in defeating the extended-release formulation. Results support that HYSINGLA ER resists crushing, breaking, and dissolution using a variety of tools and solvents and retains some extended-release properties despite manipulation. When subjected to an aqueous environment, HYSINGLA ER gradually forms a viscous hydrogel (i.e., a gelatinous mass) that resists passage through a hypodermic needle.

Clinical Abuse Potential Studies

Studies in Non-dependent Opioid Abusers

Two randomized, double-blind, placebo and active-comparator studies in non-dependent opioid abusers were conducted to characterize the abuse potential of HYSINGLA ER following physical manipulation and administration via the intranasal and oral routes. For both studies, drug liking was measured on a bipolar drug liking scale of 0 to 100 where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking, and 100 represents maximum liking. Response to whether the subject would take the study drug again was measured on a unipolar scale of 0 to 100 where 0 represents the strongest negative response (“definitely would not take drug again”) and 100 represents the strongest positive response (“definitely would take drug again”).

Intranasal Abuse Potential Study

In the intranasal abuse potential study, 31 subjects were dosed and 25 subjects completed the study. Treatments studied included intranasally administered tampered HYSINGLA ER 60 mg tablets, powdered hydrocodone bitartrate 60 mg, and placebo. Incomplete dosing due to granules falling from the subjects’ nostrils occurred in 82% (n = 23) of subjects receiving tampered HYSINGLA ER compared to no subjects with powdered hydrocodone or placebo.

The intranasal administration of tampered HYSINGLA ER was associated with statistically significantly lower mean and median scores for drug

liking and take drug again ($P < 0.001$ for both), compared with powdered hydrocodone as summarized in Table 3.

Table 3. Summary of Maximum Scores (E_{max}) on Drug Liking and Take Drug Again VAS Following intranasal Administration of HYSINGLA ER and Hydrocodone Powder in Non-dependent Opioid Abusers

VAS Scale (100 point)	HYSINGLA ER	Hydrocodone
Intranasal (n=25)	Manipulated	Powder
Drug Liking*		
Mean (SE)	65.4 (3.7)	90.4 (2.6)
Median (Range)	56 (50–100)	100 (51–100)
Take Drug Again**		
Mean (SE)	36.4 (8.2)	85.2 (5.0)
Median (Range)	14 (0–100)	100 (1–100)


*Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)

** Unipolar scale (0=maximum negative response, 100=maximum positive response)

Figure 1 demonstrates a comparison of peak drug liking scores for tampered HYSINGLA ER compared with powdered hydrocodone in subjects (n = 25) who received both treatments intranasally. The Y-axis represents the percent of subjects attaining a percent reduction in peak drug liking scores for tampered HYSINGLA ER vs. hydrocodone powder greater than or equal to the value on the X-axis.

Approximately 80% (n = 20) of subjects had some reduction in drug liking with tampered HYSINGLA ER relative to hydrocodone powder. Sixty-eight percent (n = 17) of subjects had a reduction of at least 30% in drug liking with tampered HYSINGLA ER compared with hydrocodone powder, and approximately 64% (n = 16) of subjects had a reduction of at least 50% in drug liking with tampered HYSINGLA ER compared with hydrocodone powder. Approximately 20% (n = 5) of subjects had no reduction in liking with tampered HYSINGLA ER relative to hydrocodone powder.

Figure 1: Percent Reduction Profiles for E_{max} of Drug Liking VAS for Manipulated HYSINGLA ER vs. Hydrocodone Powder, N = 25 Following Intranasal Administration



Oral Abuse Potential Study

In the oral abuse potential study, 40 subjects were dosed and 35 subjects completed the study. Treatments studied included oral administrations of chewed HYSINGLA ER 60 mg tablets, intact HYSINGLA ER 60 mg tablets, 60 mg aqueous hydrocodone bitartrate solution, and placebo.

The oral administration of chewed and intact HYSINGLA ER was associated with statistically lower mean and median scores on scales that measure drug liking and desire to take drug again ($P < 0.001$), compared to hydrocodone solution as summarized in Table 4.

Table 4. Summary of Maximum Scores (E_{max}) on Drug Liking and Take Drug Again VAS Following Oral Administration of HYSINGLA ER and Hydrocodone Solution in Non-dependent Recreational Opioid Users

VAS Scale (100 point)	HYSINGLA ER		Hydrocodone Solution
Oral (n=35)	Intact	Chewed	
Drug Liking*			
Mean (SE)	63.3 (2.7)	69.0 (3.0)	94.0 (1.7)
Median (Range)	58 (50–100)	66 (50–100)	100 (51–100)
Take Drug Again**			
Mean (SE)	34.3 (6.1)	44.3 (6.9)	89.7 (3.6)
Median (Range)	24 (0–100)	55 (0–100)	100 (1–100)


*Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)

** Unipolar scale (0=maximum negative response, 100=maximum positive response)

Figure 2 demonstrates a comparison of peak drug liking scores for chewed HYSINGLA ER compared with hydrocodone solution in subjects who received both treatments orally. The Y-axis represents the percent of subjects attaining a percent reduction in peak drug liking scores for chewed HYSINGLA ER vs. hydrocodone solution greater than or equal to the value on the X-axis.

Approximately 80% (n = 28) of subjects had some reduction in drug liking with chewed HYSINGLA ER relative to hydrocodone solution. Approximately 69% (n = 24) of subjects had a reduction of at least 30% in drug liking with chewed HYSINGLA ER compared with hydrocodone solution, and approximately 60% (n = 21) of subjects had a reduction of at least 50% in drug liking with chewed HYSINGLA ER compared with hydrocodone solution. Approximately 20% (n = 7) of subjects had no reduction in drug liking with chewed HYSINGLA ER relative to hydrocodone solution.

Figure 2. Percent Reduction Profiles for E_{max} of Drug Liking VAS for Chewed HYSINGLA ER vs. Hydrocodone Solution, N = 35 Following Oral Administration



The results of a similar analysis of drug liking for intact HYSINGLA ER relative to hydrocodone solution were comparable to the results of chewed HYSINGLA ER relative to hydrocodone solution. Approximately 83% (n = 29) of subjects had some reduction in drug liking with intact HYSINGLA ER relative to hydrocodone solution. Eighty-three percent (n = 29) of subjects had a reduction of at least 30% in peak drug liking scores with intact HYSINGLA ER compared to hydrocodone solution, and approximately 74% (n = 26) of subjects had a reduction of at least 50% in peak drug liking scores with intact HYSINGLA ER compared with hydrocodone solution. Approximately 17% (n = 6) had no reduction in drug liking with intact HYSINGLA ER relative to hydrocodone solution.

Summary

The *in vitro* data demonstrate that HYSINGLA ER has physical and chemical properties that are expected to deter intranasal and intrave-

nous abuse. The data from the clinical abuse potential studies, along with support from the *in vitro* data, also indicate that HYSINGLA ER has physicochemical properties that are expected to reduce intranasal abuse and oral abuse when chewed. However, abuse of HYSINGLA ER by the intravenous, intranasal, and oral routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of HYSINGLA ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

HYSINGLA ER contains hydrocodone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit, including fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. HYSINGLA ER can be abused and is subject to misuse, addiction, and criminal diversion [See *Warnings and Precautions (5.1) and Drug Abuse and Dependence (9)*].

9.3 Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.

HYSINGLA ER should be discontinued by a gradual downward titration [see *Dosage and Administration (2.6)*]. If HYSINGLA ER is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, piloerection, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, increased blood pressure, respiratory rate, or heart rate. Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms [see *Warnings and Precautions (5.3) and Use in Specific Populations (8.3)*].

10 OVERDOSAGE

10.1 Symptoms

Acute overdose with opioids is often characterized by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, sometimes, pulmonary edema, bradycardia, hypotension, and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations [see *Clinical Pharmacology (12.2)*].

10.2 Treatment

In the treatment of HYSINGLA ER overdose, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation.

Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias will require advanced life support techniques.

The opioid antagonist naloxone hydrochloride is a specific antidote against respiratory depression that may result from opioid overdose. Nalmefene is an alternative opioid antagonist, which may be administered as a specific antidote to respiratory depression resulting from opioid overdose. Since the duration of action of HYSINGLA ER may exceed that of the antagonist, keep the patient under continued surveillance and


administer repeated doses of the antagonist according to the antagonist labeling, as needed, to maintain adequate respiration.

Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression. Administer opioid antagonists cautiously to persons who are known, or suspected to be, physically dependent on HYSINGLA ER. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. In an individual physically dependent on opioids, administration of the usual dose of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.

11 DESCRIPTION

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets are supplied in 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg and 120 mg film-coated tablets for oral administration. The tablet strengths describe the amount of hydrocodone per tablet as the bitartrate salt.

Hydrocodone bitartrate is an opioid agonist. Its chemical name is 4,5 α -epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). Its structural formula is:



Empirical formula: $C_{18}H_{21}NO_3 \cdot C_4H_6O_6 \cdot 2\frac{1}{2}H_2O$;
Molecular weight: 494.49.

Hydrocodone bitartrate exists as fine white crystals or a crystalline powder. It is affected by light. It is soluble in water, slightly soluble in alcohol, and insoluble in ether and chloroform.

The 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg and 120 mg tablets contain the following inactive ingredients: Butylated Hydroxytoluene (BHT, an additive in Polyethylene Oxide), Hydroxypropyl Cellulose, Macrogon/PEG 3350, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Oxide, Polysorbate 80, Polyvinyl Alcohol, Talc, Titanium Dioxide, and Black Ink.

The 20 mg tablets also contain Iron Oxide Yellow and FD&C Blue #2 Aluminum Lake/Indigo Carmine Aluminum Lake.

The 30 mg tablets also contain Iron Oxide Yellow.

The 40 mg tablets also contain Iron Oxide Yellow, Iron Oxide Red, and Iron Oxide Black.

The 60 mg tablets also contain Iron Oxide Yellow and Iron Oxide Red.

The 80 mg tablets also contain Iron Oxide Red.

The 100 mg tablets also contain FD&C Blue #2 Aluminum Lake.

Black Ink Contains: Shellac Glaze (in Ethanol), Isopropyl Alcohol, Iron Oxide Black, N-Butyl Alcohol, Propylene Glycol and Ammonium Hydroxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Hydrocodone is a semi-synthetic opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Hydrocodone acts as an agonist binding to and activating opioid receptors in the brain and spinal cord, which are coupled to G-protein complexes and modulate synaptic transmission through adenylate cyclase. The pharmacological effects of hydrocodone including analgesia, euphoria, respiratory depression and physiological dependence are believed to be primarily mediated via μ opioid receptors.

12.2 Pharmacodynamics

Cardiac Electrophysiology

QTc interval prolongation was studied in a double-blind, placebo- and positive-controlled 3-treatment parallel-group, dose-escalating study of HYSINGLA ER in 196 healthy subjects. QTc interval prolongation was

observed following HYSINGLA ER 160 mg per day. The maximum mean (90% upper confidence bound) difference in the QTc interval between HYSINGLA ER and placebo (after baseline-correction) at steady state was 6 (9) milliseconds, 7 (10) milliseconds, and 10 (13) milliseconds at HYSINGLA ER doses of 80 mg, 120 mg and 160mg respectively. For clinical implications of the prolonged QTc interval, see Warnings and Precautions (5.14).

Central Nervous System

The principal therapeutic action of hydrocodone is analgesia. In common with other opioids, hydrocodone causes respiratory depression, in part by a direct effect on the brainstem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Opioids depress the cough reflex by direct effect on the cough center in the medulla.

Hydrocodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see *Overdosage* (10.1)]. In addition to analgesia, the widely diverse effects of hydrocodone include drowsiness, changes in mood, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system [see *Clinical Pharmacology* (12.2)].

Gastrointestinal Tract and Other Smooth Muscle

Hydrocodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Cardiovascular System

Hydrocodone may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Endocrine System

Opioids may influence the hypothalamic-pituitary-adrenal or -gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.

Immune System

In vitro and animal studies indicate that opioids have a variety of effects on immune functions, depending on the context in which they are used. The clinical significance of these findings is unknown.

Concentration/Exposure—Efficacy Relationships

The minimum effective plasma concentration of hydrocodone for analgesia varies widely among patients, especially among patients who have been previously treated with agonist opioids. As a result, titrate the doses of individual patients to achieve a balance between therapeutic and adverse effects. The minimum effective analgesic concentration of hydrocodone for any individual patient may increase over time due to an increase in pain, progression of disease, development of a new pain syndrome and/or potential development of analgesic tolerance.

Concentration/Exposure—Adverse Experience Relationships

There is a general relationship between increasing opioid plasma concentration and increasing frequency of adverse experiences such as nausea, vomiting, CNS effects, and respiratory depression. As with all opioids, the dose of HYSINGLA ER must be individualized [see *Dosage and Administration* (2.1, 2.2)]. The effective analgesic dose for some patients will be too high to be tolerated by other patients.

12.3 Pharmacokinetics

Absorption

HYSINGLA ER is a single-entity extended-release formulation of hydrocodone that yields a gradual increase in plasma hydrocodone concentrations with a median T_{max} of 14 – 16 hours noted for different dose

strengths. Peak plasma levels may occur in the range of 6 -30 hours after single dose HYSINGLA ER administration.

Systemic exposure (AUC and C_{max}) increased linearly with doses from 20 to 120 mg. Both C_{max} and AUC increased slightly more than dose proportionally (Table 5). The mean terminal half-life ($t_{1/2}$) was similar for all HYSINGLA ER dose strengths ranging from 7 to 9 hours.


Table 5 Mean (SD) Single-Dose Pharmacokinetic Parameters of HYSINGLA ER

Dose Strength (mg)	AUCinf (ng•h/mL)	C_{max} (ng/mL)	T_{max} * (h)
20	284 (128)	14.6 (5.5)	16 (6, 24)
40	622 (252)	33.9 (11.8)	16 (6, 24)
60	1009 (294)	53.6 (15.4)	14 (10, 30)
80	1304 (375)	69.1 (17.2)	16 (10, 24)
120	1787 (679)	110 (44.1)	14 (6, 30)

* median (minimum, maximum)

As compared to an immediate-release hydrocodone combination product, HYSINGLA ER at the same daily dose results in similar bioavailability but with lower maximum concentrations at steady state. (Figure 3).

Figure 3. Mean Steady-State Plasma Hydrocodone Concentration Profile



Steady-state plasma hydrocodone concentrations were confirmed on day 3 of once-daily dosing of HYSINGLA ER. The extent of accumulation of systemic exposure was 1.3 and 1.1 fold with respect to AUC and C_{max} at steady-state. The mean terminal half-life ($t_{1/2}$) at steady state was 7 hours. Median T_{max} values were 14 hours (range: 12 to 24 hours) on both Day 1 and Day 5 following once daily administration of HYSINGLA ER for five days. Daily fluctuation in peak to trough plasma levels of hydrocodone were higher at 80 mg and 120 mg doses of HYSINGLA ER compared to 30 mg dose (Table 6).

Table 6 Mean (SD) Steady-State Hydrocodone Pharmacokinetic Parameters

Regimen	AUC _{24,ss} (ng•h/mL)	$C_{max,ss}$ (ng/mL)	$C_{min,ss}$ (ng/mL)	%Fluctuation*
HYSINGLA ER				
30 mg q24h	443 (128)	26.4 (7.4)	16.7 (5.2)	61 (6.4,113)
80 mg q24h	1252 (352)	82.6 (25.7)	28.2 (12)	105 (36,214)
120 mg q24h	1938 (729)	135 (50)	63.6 (29)	97.9 (32, 250)

* Mean (minimum, maximum); Percentage fluctuation in plasma concentration is derived as $(C_{max,ss} - C_{min,ss}) * 100 / C_{avg,ss}$.

Food Effects

C_{max} and AUC of HYSINGLA ER 120 mg tablets were similar under low fat conditions relative to fasting conditions (17% and 9% higher, respectively). C_{max} was higher (54%) under high fat conditions relative to fasting

conditions; however, AUC of HYSINGLA ER 120 mg tablets was only 20% higher when co-administered with a high fat meal. HYSINGLA ER may be administered without regard to meals.

Distribution

Following administration of HYSINGLA ER, the typical (70 kg adult) value of apparent volume of distribution (V/F) is 402 L, suggesting extensive tissue distribution. The extent of *in vivo* binding of hydrocodone to human plasma proteins was minimal with a mean % bound at 36%.

Elimination

Metabolism

Hydrocodone exhibits a complex pattern of metabolism, including *N*-demethylation, *O*-demethylation, and 6-keto reduction to the corresponding 6- α - and 6- β -hydroxy metabolites. CYP3A4 mediated *N*-demethylation to inactive norhydrocodone is the primary metabolic pathway of hydrocodone with a lower contribution from CYP2B6 and CYP2C19. The minor metabolite hydromorphone (<3% of the circulating parent hydrocodone) was mainly formed by CYP2D6 mediated *O*-demethylation with a smaller contribution by CYP2B6 and CYP2C19. Hydromorphone may contribute to the total analgesic effect of hydrocodone.

Excretion

Hydrocodone and its metabolites are cleared primarily by renal excretion. The percent of administered dose excreted unchanged as hydrocodone in urine was 6.5% in subjects with normal renal function, and 5.0%, 4.8%, and 2.3% in subjects with mild, moderate, and severe renal impairment, respectively. Renal clearance (CL_r) of hydrocodone in healthy subjects was small (5.3 L/h) compared to apparent oral clearance (CL/F, 83 L/h); suggesting that non-renal clearance is the main elimination route. Ninety-nine percent of the administered dose is eliminated within 72 hours. The mean terminal half-life ($t_{1/2}$) was similar for all HYSINGLA ER dose strengths ranging from approximately 7 to 9 hours across the range of doses.

Specific Populations

Elderly (≥65 years)

Following administration of 40 mg HYSINGLA ER, the pharmacokinetics of hydrocodone in healthy elderly subjects (65 to 77 years) are similar to the pharmacokinetics in healthy younger subjects (20 to 45 years). There were no clinically meaningful increase in C_{max} (16%) and AUC (15%) of hydrocodone in elderly as compared with younger adult subjects [see Use in Specific Populations (8.5)].

Gender

Systemic exposure of hydrocodone (C_{max} and AUC) was similar between males and females.

Hepatic Impairment

After a single dose of 20 mg HYSINGLA ER in subjects (8 each) with normal hepatic function, mild, moderate or severe hepatic impairment based on Child-Pugh classifications, mean hydrocodone C_{max} values were 16, 15, 17, and 18 ng/mL, respectively. Mean hydrocodone AUC values were 342, 310, 390, and 415 ng.hr/mL for subjects with normal hepatic function, mild, moderate or severe hepatic impairment, respectively. Geometric mean hydrocodone C_{max} values were -6%, 5%, and 5% and AUC values were -14%, 13%, and 4% in patients with mild, moderate or severe hepatic impairment, respectively, when compared with subjects with normal hepatic function.

The mean *in vivo* plasma protein binding of hydrocodone across the groups was similar, ranging from 33% to 37% [see Use in Specific Populations (8.6)].

Renal Impairment

After a single dose of 60 mg HYSINGLA ER in subjects (8 each) with normal renal function, mild, moderate, or severe renal impairment based on Cockcroft-Gault criteria and end stage renal disease (with dialysis) patients, mean hydrocodone C_{max} values were 40, 50, 51, 46, and 38 ng/mL, respectively. Mean hydrocodone AUC values were 754, 942, 1222, 1220, and 932 ng.hr/mL for subjects with normal renal function, mild, moderate or severe renal impairment and ESRD with dialysis, respectively. Hydrocodone C_{max} values were 14%, 23%, 11% and -13% and AUC values were 13%, 61%, 57% and 4% higher in patients with mild, moderate or severe renal impairment or end stage renal disease with dialysis, respectively [see Use in Specific Populations (8.7)].

Drug Interaction Studies

CYP3A4

Co-administration of HYSINGLA ER (20 mg single dose) and CYP3A4 inhibitor ketoconazole (200 mg BID for 6 days) increased mean hydrocodone AUC and C_{max} by 135% and 78%, respectively [see Warnings and Precautions (5.11) and Drug Interactions (7.1)].

CYP2D6

The 90% confidence interval (CI) of the geometric means for hydrocodone AUC_{inf} (98 to 115%), AUC_t (98 to 115%), and C_{max} (93 to 121%) values were within the range of 80 to 125% when a single dose of HYSINGLA ER 20 mg was co-administered with CYP2D6 inhibitor paroxetine (20 mg treatment each morning for 12 days). No differences in systemic exposure of hydrocodone were observed in the presence of paroxetine.

13 NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Hydrocodone was evaluated for carcinogenic potential in rats and mice. In a two-year bioassay in rats, doses up to 25 mg/kg in males and females were administered orally and no treatment-related neoplasms were observed (exposure is equivalent to 0.2-fold the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons). In a two-year bioassay in mice, doses up to 200 mg/kg in males and 100 mg/kg in females were administered orally and no treatment-related neoplasms were observed (exposure is equivalent to 3.5-fold and 3.0-fold, respectively, the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons).

Mutagenesis

Hydrocodone was genotoxic in the mouse lymphoma assay in the presence of rat S9 metabolic activation but not in the absence of rat metabolic activation. However, hydrocodone was not genotoxic in the mouse lymphoma assay with or without human S9 metabolic activation. There was no evidence of genotoxic potential with hydrocodone in an *in vitro* bacterial reverse mutation assay with *Salmonella typhimurium* and *Escherichia coli* with or without metabolic activation or in an *in vivo* mouse bone marrow micronucleus test with or without metabolic activation.

Impairment of Fertility

No effect on fertility or general reproductive performance was seen with oral administration of hydrocodone to male and female rats at doses up to 25 mg/kg/day (approximately 0.06-fold and 0.08-fold, respectively, the human hydrocodone dose of 120 mg/day based on AUC exposure comparisons).

14 CLINICAL STUDIES

The efficacy and safety of HYSINGLA ER was evaluated in a randomized double-blind, placebo-controlled, multi-center, 12-week clinical trial in both opioid-experienced and opioid-naïve patients with moderate to severe chronic low back pain.

14.1 Moderate to Severe Chronic Lower Back Pain Study

A total of 905 chronic low back pain patients (opioid naïve and opioid-experienced) who were not responsive to their prior analgesic therapy entered an open-label conversion and dose-titration period for up to 45 days with HYSINGLA ER. Patients were dosed once daily with HYSINGLA ER (20 to 120 mg). Patients stopped their prior opioid analgesics and/or nonopioid analgesics prior to starting HYSINGLA ER treatment. Optional use of rescue medication (immediate-release oxycodone 5 mg) up to 2 doses (2 tablets) was permitted during the dose titration period. For inadequately controlled pain, HYSINGLA ER dose was allowed to be increased once every 3–5 days until a stabilized and tolerable dose was identified. During the dose-titration period, 65% of the patients achieved a stable HYSINGLA ER dose and entered the double-blind treatment period. The remaining subjects discontinued from the dose-titration period for the following reasons: adverse events (10%); lack of therapeutic effect (5%); confirmed or suspected diver-


sion (3%); subject's choice (5%); lost to follow-up (2%); administrative reasons (2%); and failure to achieve protocol-defined reduction in pain score (7%).

Following the dose titration period, 588 patients (65%) were randomized at a ratio of 1:1 into a 12-week double-blind treatment period with their fixed stabilized dose of HYSINGLA ER (or matching placebo). These patients met the study randomization criteria of adequate analgesia (pain reduction of at least 2 points to a score of 4 or less on a 0-10 numerical rating scale) and acceptable tolerability of HYSINGLA ER. Patients randomized to placebo were given a blinded taper of HYSINGLA ER according to a pre-specified tapering schedule, 3 days on each step-down dose (reduced by 25-50% from the previous dose). Patients were allowed to use rescue medication (immediate-release oxycodone 5 mg) up to 6 doses (6 tablets) per day depending on their randomized HYSINGLA ER dose. During the double-blind period, 229 treated patients (77%) completed the 12-week treatment with HYSINGLA ER and 210 patients (72%) completed on placebo. Overall, 10% of patients discontinued due to lack of therapeutic effect (5% in HYSINGLA ER patients and 15% in placebo patients); 5% of patients discontinued due to adverse events (6% in HYSINGLA ER treated patients and 3% in placebo patients).

HYSINGLA ER provided greater analgesia compared with placebo. There was a statistically significant difference in the weekly average pain scores at Week 12 between the two groups.

The percentage of patients (responders) in each group who demonstrated improvement in their weekly average pain scores at Week 12, as compared with screening is shown in Figure 4. The figure is cumulative, so that patients whose change from screening is, for example, 30%, are also included at every level of improvement below 30%. Patients who did not complete the study were classified as non-responders. Treatment with HYSINGLA ER resulted in a higher proportion of responders, defined as patients with at least a 30% and 50% improvement, as compared with placebo.

Figure 4. Percent Improvement in Pain Intensity



16 HOW SUPPLIED/STORAGE AND HANDLING

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 20 mg are round, green-colored, bi-convex tablets printed with "HYD 20" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-271-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 30 mg are round, yellow-colored, bi-convex tablets printed with "HYD 30" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-272-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 40 mg are round, grey-colored, bi-convex tablets printed with "HYD 40" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-273-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 60 mg are round, beige-colored, bi-convex tablets printed with "HYD 60" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-274-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 80 mg are round, pink-colored, bi-convex tablets printed with "HYD 80" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-275-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 100 mg are round, blue-colored, bi-convex tablets printed with "HYD 100" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-276-60).

HYSINGLA ER (hydrocodone bitartrate) extended-release tablets 120 mg are round, white-colored, bi-convex tablets printed with "HYD 120" and are supplied in child-resistant closure, opaque plastic bottles of 60 (NDC 59011-277-60).

Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F).

Dispense in tight, light-resistant container, as defined by the USP.

CAUTION

DEA FORM REQUIRED

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide)

Addiction, Abuse, and Misuse

Inform patients that the use of HYSINGLA ER, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose or death [see *Warnings and Precautions* (5.1)]. Instruct patients not to share HYSINGLA ER with others and to take steps to protect HYSINGLA ER from theft or misuse.

Life-Threatening Respiratory Depression

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting HYSINGLA ER or when the dose is increased, and that it can occur even at recommended doses [see *Warnings and Precautions* (5.2)]. Advise patients how to recognize respiratory depression and to seek medical attention if they are experiencing breathing difficulties.

Accidental Consumption

Inform patients that accidental exposure, especially in children, may result in respiratory depression or death [see *Warnings and Precautions* (5.2)]. Instruct patients to take steps to store HYSINGLA ER securely and to dispose of unused HYSINGLA ER in accordance with local state guidelines and/or regulations.

Neonatal Opioid Withdrawal Syndrome

Inform female patients of reproductive potential that chronic use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see *Warnings and Precautions* (5.3)].

Interaction with Alcohol and other CNS Depressants

Inform patients that the concomitant use of alcohol with HYSINGLA ER can increase the risk of life-threatening respiratory depression [see *Warnings and Precautions* (5.4)]. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter products that contain alcohol, during treatment with HYSINGLA ER. Inform patients that potentially serious additive effects may occur if HYSINGLA ER is used with alcohol or other CNS depressants, and not to use such drugs unless supervised by a health care provider.

Important Administration Instructions

Instruct patients how to properly take HYSINGLA ER, including the following:

- The tablets must be swallowed whole and must not be chewed, crushed, or dissolved. Taking chewed, crushed or dissolved HYSINGLA ER tablets or contents can lead to rapid release and absorption of a potentially fatal dose of hydrocodone.
- Use HYSINGLA ER exactly as prescribed to reduce the risk of life-threatening adverse reactions (e.g., respiratory depression).
- Contact prescriber if pain control is not adequate or if there are ad-

verse reactions occurring during therapy.

- Do not discontinue HYSINGLA ER without first discussing the need for a tapering regimen with the prescriber.
- HYSINGLA ER tablets should be taken one tablet at a time.
- Do not pre-soak, lick or otherwise wet the tablet prior to placing in the mouth which may result in difficulty swallowing HYSINGLA ER tablets.
- Take each tablet with enough water to ensure complete swallowing immediately after placing in the mouth.

Hypotension

Inform patients that HYSINGLA ER may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position).

Driving or Operating Heavy Machinery

Inform patients that HYSINGLA ER may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Blood levels of hydrocodone, in some patients, may be high at the end of 24 hours after repeated dose administration. Advise patients not to perform such tasks until they know how they will react to the medication.

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention. Instruct patients to monitor their analgesic response following the use of strong laxatives and to contact the prescriber if changes are noted.

QT interval prolongation

Inform patients that QT prolongation has been observed with HYSINGLA ER [see *Clinical Pharmacology* (12.2)]. HYSINGLA ER should be avoided in patients with congenital long QT syndrome. Instruct patients with a history of congestive heart failure or bradyarrhythmias, and patients at risk for electrolyte abnormalities or who are taking other medications known to prolong the QT interval that periodic monitoring of electrocardiograms and electrolytes may be necessary during therapy with HYSINGLA ER.

Anaphylaxis

Inform patients that anaphylaxis has been reported with ingredients contained in HYSINGLA ER. Advise patients how to recognize such a reaction and when to seek medical attention.

Pregnancy

Advise female patients that HYSINGLA ER may cause fetal harm and to inform the prescriber if they are pregnant or plan to become pregnant.

Nursing Mothers

Advise female patients that HYSINGLA ER passes into human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue drug [see *Use in Specific Populations* (8.3)].

Disposal of unused HYSINGLA ER

Advise patients to dispose of any unused tablets from a prescription as soon as they are no longer needed in accordance with local state guidelines and/or regulations.

Healthcare professionals can telephone Purdue Pharma's Medical Services Department (1-888-726-7535) for information on this product.

Purdue Pharma L.P.

Stamford, CT 06901-3431

©2015, Purdue Pharma L.P.

U.S. Patent Numbers: 6,488,963; 6,733,783; 8,309,060; 8,361,499; 8,529,948; 8,551,520; 8,647,667 and 8,808,740.

Medication Guide

HYSINGLA™ ER (hye-SING-luh)

(hydrocodone bitartrate) extended-release tablets, CII

HYSINGLA ER is:

- A strong prescription pain medicine that contains an opioid (narcotic). It is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.
- A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.
- Not for use to treat pain that is not around-the-clock.

Important information about HYSINGLA ER:

- Get emergency help right away if you take too much HYSINGLA ER (overdose). When you first start taking HYSINGLA ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur.
- Never give anyone else your HYSINGLA ER. They could die from taking it. Store HYSINGLA ER away from children and in a safe place to prevent stealing or abuse. Selling or giving away HYSINGLA ER is against the law.

Do not take HYSINGLA ER if you have:

- severe asthma, trouble breathing, or other lung problems.
- a bowel blockage or have narrowing of the stomach or intestines.

Before taking HYSINGLA ER, tell your healthcare provider if you have a history of:

- head injury, seizures
- liver, kidney, thyroid problems
- problems urinating
- pancreas or gallbladder problems
- heart rhythm problems (long QT syndrome)
- abuse of street or prescription drugs, alcohol addiction, or mental health problems

Tell your healthcare provider if you are:

- **pregnant or planning to become pregnant.** Prolonged use of HYSINGLA ER during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.
- **breastfeeding.** HYSINGLA ER passes into breast milk and may harm your baby.
- taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking HYSINGLA ER with certain other medicines can cause serious side effects and could lead to death.

When taking HYSINGLA ER:

- Do not change your dose. Take HYSINGLA ER exactly as prescribed by your healthcare provider.
- Take your prescribed dose every 24 hours, at the same time every day. Do not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual time the next day.
- Swallow HYSINGLA ER whole. Do not cut, break, chew, crush, dissolve, snort, or inject HYSINGLA ER because this may cause you to overdose and die.
- HYSINGLA ER should be taken 1 tablet at a time. Do not pre-soak, lick, or wet the tablet before placing it in your mouth to avoid choking on the tablet.

Call your healthcare provider if the dose you are taking does not control your pain.

- **Do not stop taking HYSINGLA ER without talking to your healthcare provider.**
- After you stop taking HYSINGLA ER, flush any unused tablets down the toilet.

While taking HYSINGLA ER, DO NOT:

- Drive or operate heavy machinery until you know how HYSINGLA ER affects you. HYSINGLA ER can make you sleepy, dizzy, or lightheaded.
- Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with HYSINGLA ER may cause you to overdose and die.

The possible side effects of HYSINGLA ER are:

- constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

Get emergency medical help if you have:

- trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme drowsiness, light-headedness when changing positions, or you are feeling faint.

These are not all the possible side effects of HYSINGLA ER. Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov

Manufactured by: Purdue Pharma L.P., Stamford, CT 06901-3431, www.purduepharma.com or call 1-888-726-7535

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Issue: 11/2014



303511-00 HYD011

**WALGREEN CO.
PRODUCT UPDATE
MASTER SERVICES AGREEMENT**

This **Product Update Master Services Agreement** (“Agreement”) is entered into as of the 17th day of March 2015 (“Effective Date”), by and between **Purdue Pharma L.P.**, a limited partnership with its principal place of business at One Stamford Forum, Stamford, CT 06901 (“Client), and **Walgreen Co.**, an Illinois corporation, on behalf of itself and its retail pharmacy subsidiaries and affiliates, with offices located at 1417 Lake Cook Road, Deerfield, IL 60015 (“Walgreens”).

WHEREAS, Walgreens on occasion creates communication updates (“Communications”) to provide its pharmacists or customers with clinical and product information or education regarding a certain pharmaceutical product;

WHEREAS, Client manufactures certain pharmaceutical products that it desires Walgreens to create Communications for distribution to Walgreens’ pharmacists and/or customers; and

WHEREAS, Walgreens is willing to develop and produce Communications featuring Client’s pharmaceutical product (“Product”) as described in any exhibit to this Agreement (“Exhibit”), the format substantially similar to the attached sample exhibit attached hereto as Attachment A and incorporated herein, pursuant to the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the mutual terms, conditions and covenants hereinafter set forth, Client and Walgreens agree as follows:

1. Services

1.1 **Description of Services.** Upon request and mutual agreement, Walgreens will create a Communication(s) featuring a Product as described in each Exhibit attached and incorporated hereunder. Each Exhibit should be numbered sequentially (e.g., **Exhibit 1, Exhibit 2, etc.**). Client acknowledges and agrees that the sole purpose of a Communication is to provide certain clinical information regarding a Product to Walgreens’ retail pharmacists and/or customers. The parties acknowledge that payments received under this Agreement are not dependent on any volume of the Product prescriptions dispensed. The parties agree that such payments are consistent with fair market value in an arms-length transaction for the services being provided. The parties further acknowledge and agree that the payments received by Walgreens from Client: (i) are intended solely for payment in consideration for the applicable Communication services, (ii) do not exceed that which is reasonably necessary to accomplish the parties’ commercially reasonable business purpose pursuant to this Agreement, and (iii) do not reflect a direct or indirect discount, rebate, or other price reduction on the purchase price of any product or goods manufactured or sold by Client or its affiliates to Walgreens, if any, and will not be used in such a manner either directly or indirectly.

1.2 **Communication.** The purpose of a Communication is to allow Client to deliver Product messages to Walgreens’ retail pharmacies and/or customers. Walgreens will deliver the Communication in accordance with the applicable Exhibit(s). Product message design on each Communication will appear as approved and mutually agreed to by the parties in writing. Client shall approve any product-related materials, prior to distribution under this Agreement, and shall retain all intellectual property rights in the Client Materials distributed hereunder. No product-related materials may be distributed without Client’s approval.

1.3 **Distribution of Communication.** A description of how a Communication will be distributed will be set forth in each Exhibit. Client acknowledges and agrees that in no event shall this Agreement be construed or interpreted as requiring a Communication to be published or distributed in a manner other than as set forth in an Exhibit. Walgreens shall not distribute any information or materials under this Agreement without prior written approval from Client.

2. **Term & Termination**

2.1 **Term.** The term of this Agreement shall commence on the Effective Date and will continue through February 10, 2017, or until this Agreement is terminated as provided herein.

2.2 **Without Cause Termination.** Either party may terminate this Agreement at any time without cause upon at least 30 days prior written notice to the other party.

2.3 **With Cause Termination.** Either party may terminate this Agreement for cause at any time upon at least 10 business days' prior written notice to the other party. "Cause" means (i) material breach by either party of this Agreement where such breach, if curable, is not remedied to the other party's reasonable satisfaction within such 10 business day period, (ii) a voluntary or involuntary proceeding in bankruptcy is filed by or on behalf of the other party.

2.4 **Post Termination Obligations.** Upon termination of this Agreement, Client will nonetheless remain liable to compensate Walgreens for any work or services contemplated herein and performed prior to the termination date or for any non-cancelable commitments contemplated herein and entered into by Walgreens prior to the notice of termination.

3. **Service Fees**

3.1 **Compensation.** Walgreens' fee for producing the Communication shall be set forth in an Exhibit. Unless otherwise stated in an Exhibit, Walgreens shall invoice Client and Client's payment shall be due within 30 days of receipt of the invoice. Walgreens shall mail invoices to:

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901
ATTN: Steve Projansky, Director, Strategy & Marketing

If Company requires a Purchase Order or similar document to process invoices, Company will create any applicable Purchase Order or similar document upon execution of contract and provide Walgreens with applicable Purchase Order within 15 days of contract execution. Company will send payment to Walgreens for all invoiced amounts within thirty (30) days after the receipt of the invoice. Company agrees to provide an email notification for each invoice payment to both elena.suvarova@walgreens.com and greg.lindquist@walgreens.com. Payments will be sent to:

For electronic transmission:
Bank of America
ACH Account No. 3756250703
Routing No. 111000012

4. Confidentiality

4.1 **Confidential Information.** In connection with the performance of the services contemplated by this Agreement, the parties may receive or have access to proprietary and confidential materials and information belonging to the other party. All such materials and information (including without limitation technical, scientific, financial, strategic, marketing or product information) are collectively defined as “Confidential Information” and constitute the exclusive property of the owner of the property. For a period of three years from the date of disclosure, the party receiving the Confidential Information will not use (except to perform the services contemplated by this Agreement) or disclose to third parties the Confidential Information without the disclosing party’s written consent. The receiving party shall also limit disclosure of Confidential Information within its organization to those persons who need to know such Confidential Information in order to provide the services contemplated by this Agreement. The confidentiality obligations set forth in this Section shall survive the termination or expiration of this Agreement for a period of three years.

4.2 **Permitted Disclosures.** The parties agree that the confidentiality obligations set forth above shall not apply to any Confidential Information which:

- (a) is or shall become public knowledge through no fault of the receiving party;
- (b) is already in the receiving party’s possession (as evidenced by written records pre-dating receipt from the disclosing party);
- (c) becomes available to the receiving party from another source without any limitations on disclosure; or
- (d) is independently developed by the receiving party without use or reliance upon the Confidential Information disclosed by the disclosing party.

In the event that the receiving party is required by law, regulation, rule, act, or order of any governmental authority or agency to disclose Confidential Information, the receiving party shall give the disclosing party sufficient advance written notice to permit the disclosing party to seek a protective order or other similar order with respect to such Confidential Information and thereafter shall disclose only the minimum information required to be disclosed in order to comply.

5. Indemnification

5.1 **Mutual Indemnification.** Each party shall defend, indemnify and hold the other party and its directors, officers, employees, shareholders, and agents harmless from any of all third party claims, demands, liability, damage, loss, suits and/or judgments, including, but not limited to, attorneys’ fees and the cost of any judgment and settlements arising out of or in connection with the negligent performance of that party under the terms of this Agreement, the violation of applicable law by that party or breach of this Agreement by that party. The party providing indemnification hereunder (“Indemnifying Party”) will be promptly notified of any injury or claim that the other party (“Indemnified Party”) is made aware of. The Indemnified Party agrees to cooperate in assisting the Indemnifying Party in presenting a defense, if requested to do so.

6. Representations and Warranties

6.1 Mutual Representations and Warranties. Each party hereby warrants, represents and covenants to the other party as follows:

(i) such party is and at all times during the term of this Agreement shall remain a corporation/limited liability company duly organized, validly existing and in good standing under the laws of its jurisdiction of organization;

(ii) such party (i) has the corporate power, authority and legal right to enter into this Agreement and to perform its obligations hereunder; and (ii) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;

(iii) neither party is under any contractual or other obligation or restriction which would prevent or prohibit said party's execution of this Agreement or the performance of its obligations hereunder;

(iv) such party shall at all times comply with all laws applicable to the performance of its obligations hereunder; and

(v) such party's performance of its obligations hereunder shall not infringe the intellectual property rights of a third party.

6.2 Walgreens' Representations and Warranties. Walgreens warrants, represents and covenants that it shall fully reproduce the Product message as approved and as mutually agreed upon in writing by the parties.

6.3 Client's Representations and Warranties. Client warrants, represents and covenants that all materials, data or other information provided by Client to Walgreens (collectively, the "**Client Materials**"): (i) shall comply with all applicable laws and regulations, (i) shall be scientifically accurate and claims made therein shall be true and shall have been substantiated at the time that such claims are made, and (ii) will not violate or infringe upon the rights of any third party.

7. Insurance

7.1. Mutual Insurance Requirements. Walgreens will self-insure or maintain at its sole expense, and in amounts consistent with industry standards, insurance for general liability and such other insurance as may be necessary to insure Walgreens, its employees and agents against any claim or claims for damages arising out of or in connection with the negligent performance of its duties and obligations under this Agreement. Walgreens' insurance information is available for review and printing at www.walgreens.com/insurance. Client will self-insure or maintain at its sole expense, and in amounts consistent with industry standards, insurance for general liability and such other insurance as may be necessary to insure Client, its employees and agents against any claim or claims for damages arising out of or in connection with the negligent performance of its duties and obligations under this Agreement. Upon Walgreens' request, Client will provide Walgreens with evidence of its insurance coverage.

8. Ownership

8.1 Intellectual Property. Client acknowledges and agrees that Walgreens shall retain any and all rights, title and interest in any Communication(s) developed or created by Walgreens (excluding the

Client Materials). Client shall retain any and all rights, title and interest in the confidential and proprietary information furnished to Walgreens, including any data, discoveries, findings, improvements, ideas, concepts, graphics, photos, logos, brands, designs, artwork, presentations, recordings, publications, computer programs, algorithms, protocols, system and related documentation and any other works of invention or authorship (whether or not patentable, copyrightable, or entitled to or eligible for other forms of legal protection) which the Client has conceived, discovered, authored, written, invented, developed, or reduced to practice, together with all copyright, patent, trademark, trade secret and other intellectual and industrial property rights covering or embodied by any of the foregoing, related to the Product.

8.2. **Trademarks.** Subject to the terms and conditions set forth herein and solely for the purposes hereof, Client hereby authorizes and consents to Walgreens' use and/or placement of Client's trademarks relating to the Products in a Communication, which Walgreens may include in its sole discretion.

8.3 **No License.** Except as expressly provided in this Agreement, nothing herein shall be construed as granting unto either party any license, right, title or interest in or ownership of the other party's Intellectual Property or Confidential Information.

9. **General Provisions.**

9.1. The parties to this Agreement are independent contractors and nothing herein shall be deemed to create a separate corporation, a merger, joint venture or partnership of the parties, nor shall anything be deemed to imply or create a master-servant, employer-employee, or principal agent relationship between the parties. Neither of the parties to this Agreement, nor any of their respective officers, directors or employees shall be construed to be the agent, employee, or representative of the other except as may otherwise be described in this Agreement. Neither party is authorized to speak on behalf of the other for any purpose whatsoever without the prior written consent of the other party.

9.2. Any notices required to be given pursuant to the terms and provisions hereof shall be in writing, and shall be sent by certified or registered mail, return receipt requested, or a nationally recognized delivery service with tracking provided to the respective parties at the addresses set forth below, or at such other address as such party may designate from time to time by written notice to the other party. All notices given pursuant to this Agreement shall be effective upon receipt.

Walgreen Co.
104 Wilmot Rd.
Deerfield, IL 60015
Attn.: Pharmacy Purchasing &
Development Law, MS 1425

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT
Attn.: Law Dept.

With a copy to:
Walgreen Co.
1417 Lake Cook Rd. MS L259
Deerfield, IL 60015
Attn: Todd Sauer

With a copy to:
Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901
Attn: Steve Projansky, Director, Strategy &
Marketing

Neither party shall refuse acceptance of delivery of any such notice.

9.3. This Agreement, together with any attached Exhibit(s), constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes all prior oral or written agreements, commitments or understandings with respect thereto. This Agreement may be amended at any time by mutual agreement of the parties, but no such amendment is valid unless it is in writing and signed by duly authorized representatives of both parties.

9.4. Notwithstanding any provision to the contrary, neither party shall be liable to the other party for any lost profits, consequential, incidental, indirect, special, or other similar damages whether foreseen or unforeseen, arising from or related to this Agreement.

9.5. Neither party may assign this Agreement to a third party without the prior written consent of the other party, which consent may not be unreasonably withheld; except that either party will have the right to assign this Agreement or any of the obligations contained herein to any direct or indirect parent, subsidiary or affiliated company or to a successor company. Any permitted assignee will assume all obligations of its assignor under this Agreement. No assignment will relieve any party of responsibility for the performance of any obligations, which have already occurred prior to such assignment. This Agreement will inure to the benefit of and be binding upon each party, its respective successors and permitted assignees.

9.6. Neither party shall be deemed to be in default of this Agreement if prevented from performing any obligation hereunder for any reason beyond its control, including without limitation, governmental laws and regulations, acts of "nature" or the public, flood, storm or strikes. In such case, the parties shall negotiate in good faith with the intent of preserving this Agreement and the respective rights and obligations of the parties.

9.7. In the event of a conflict between the terms and conditions of this Agreement and the terms and conditions set forth in any Exhibit(s) attached hereto, the terms and conditions set forth in the Exhibit(s) will prevail.

9.8. The validity and construction of the terms and provisions of this Agreement and the rights and obligations of the parties hereto shall be interpreted and enforced in accordance with the laws of the State of Illinois, except to the extent preempted by Federal law, and without regard to its rules on conflicts on law.

9.9. Neither the waiver by either party hereto of any breach of or default under any of the provisions of this Agreement, nor the failure of either party to enforce any of the provisions of this Agreement or to exercise any right hereunder, shall be construed as a waiver of any subsequent breach or default, or as a waiver of any such rights or provisions hereunder.

9.10. Each party represents and warrants that the individual signing this Agreement on its behalf is duly authorized to bind such party to all terms and conditions of this Agreement.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date.

WALGREEN CO.

By _____
Signature

Print Name _____

Title _____

PURDUE PHARMA L.P.

By *Stella K* _____
Signature

Print Name STELLA KADATSKAYA

Title _____

DO NOT COMPLETE

Attachment A
to
Product Update Master Services Agreement

This Exhibit ___ (“Exhibit”) is effective as of <Date> (“Exhibit # ___ Effective Date”) and is hereby incorporated into the Product Update Master Services Agreement, dated <Date>, by and between **Purdue Pharma L.P.** (“Client”) and **Walgreen Co.** (“Walgreens”).

1. SERVICES:

Walgreens will create a Communication for the following pharmaceutical product:

Manufacturer:

Product Brand Name: Drug[®] (“Product”)

Generic Name:

Communication: <describe Communication> (the “Communication”)

Based on the information provided by Client, Walgreens will develop the Communication for the Product. <insert description of how communication will be posted>

2. TOTAL FEE:

The total fee payable by Client to Walgreens to develop and publish the Communication (including development and maintenance of the Communication) shall be <insert fee>.

3. TIME LINE FOR DEVELOPMENT/IMPLEMENTATION:

- Walgreens shall submit a draft of the Communication to Client for review prior to printing and distribution. Walgreens shall finalize the Communication (including making any revisions requested by Client that Walgreens deems appropriate) and Client shall approve the pharmacy update on or about <Approval Date>.
- The Communication shall be published on or about <Distribution Start Date>.

Signature page follows

IN WITNESS WHEREOF, the parties hereto have caused this Exhibit to be executed by their duly authorized representatives as of Exhibit Effective Date.

WALGREEN CO.

By: _____ Do not
Printed Name: _____ complete, for
Title: _____ example only

PURDUE PHARMA L.P.

By: _____ Do not
Printed Name: _____ complete, for
Title: _____ example only

Exhibit 1
to
Product Update Master Services Agreement

This Exhibit 1 ("Exhibit") is effective as of March 17, 2015 ("Exhibit # 1 Effective Date") and is hereby incorporated into the Product Update Master Services Agreement, dated March 17, 2014, by and between **Purdue Pharma, L.P.** ("Client") and **Walgreen Co.** ("Walgreens").

1. SERVICES:

Walgreens will create a Communication for the following pharmaceutical product:

Manufacturer: Client

Product Brand Name: Hysingla™ ER ("Product")

Generic Name: hydrocodone bitartrate

Communication: To inform Walgreens retail pharmacists of the Product's clinical attributes (the "Communication")

Based on the information provided by Client, Walgreens will develop the Communication for the Product. In addition, Walgreens will post the Communication as a MPU Alert on Walgreens' Intranet for a minimum of six months. At the time of posting, Walgreens will send a message to its pharmacies informing them of the Communication in the weekly electronic pharmacy update bulletin distributed to Walgreens' retail pharmacies. A copy of the Communication is attached below in the form of Attachment

2. TOTAL FEE:

The total fee payable by Client to Walgreens to develop and publish the Communication (including development and maintenance of the Communication) shall be \$25,000. This total fee is not dependent on any volume of the Product prescriptions dispensed. The parties agree that the total fee is a fair market value in an arms-length transaction for the services being provided. The parties acknowledge that the service fee received by Walgreens from Client is intended solely for payment in consideration for the Communication services described herein and do not exceed that which is reasonably necessary to accomplish the parties' commercially reasonable business purpose pursuant to this Exhibit. These fees do not reflect a direct or indirect discount, rebate, or other price reduction on the purchase price of any product or goods manufactured or sold by Client or its affiliates to Walgreens, if any, and will not be used in such a manner either directly or indirectly

3. TIME LINE FOR DEVELOPMENT/IMPLEMENTATION:

Walgreens shall submit a draft of the Communication to Client for review prior to printing and distribution. Walgreens shall finalize the Communication (including making any revisions requested by Client that Walgreens deems appropriate) and Client shall approve the pharmacy update on or about March 30, 2015.

The Communication shall be published on or about April 6, 2015.

Signature page follows

IN WITNESS WHEREOF, the parties hereto have caused this Exhibit to be executed by their duly authorized representatives as of Exhibit Effective Date.


WALGREEN CO.

By: _____

Printed Name: _____

Title: _____

PURDUE PHARMA, L.P.

By:  _____

Printed Name: Stella KADATSKAYA

Title: _____